<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2708245829
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Pratima Duo
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PERINDOPRIL ARGININE,AMLODIPINE BESILATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5,10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        60.70
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jazeera Pharmaceutical Industries (JPI)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)	
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09BB04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pratima Duo is prescribed for treatment of high blood pressure (hypertension) and/or treatment of stable coronary artery disease (a condition where the blood supply to the heart is reduced or blocked). &nbsp;</p><p>Patients already taking perindopril and amlodipine from separate tablets may instead receive one tablet of Pratima Duo which contains both ingredients. &nbsp;</p><p>Pratima Duo is a combination of two active ingredients, perindopril and amlodipine.</p><p>Perindopril is an ACE (angiotensin converting enzyme) inhibitor. Amlodipine is a calcium antagonist (which belongs to a class of medicines called dihydropyridines). Together they work to widen and relax the blood vessels so that blood passes through them more easily and makes it easier for your heart to maintain a good blood flow.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Pratima Duo </strong></p><ul><li>If you are allergic to perindopril or any other ACE inhibitor, or to amlodipine or any other calcium antagonists, or any of the other ingredients of this medicine (listed in section 6)</li><li>If you are more than 3 months pregnant (It is also better to avoid Pratima Duo in early pregnancy &ndash; see pregnancy section)</li><li>If you have experienced symptoms such as wheezing, swelling of the face or tongue, intense itching or severe skin rashes with previous ACE inhibitor treatment or if you or a member of your family have had these symptoms in any other circumstances (a condition called angioedema)</li><li>If you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren</li><li>If you have narrowing of the aortic heart valve (aortic stenosis) or cardiogenic shock (a condition where your heart is unable to supply enough blood to the body)&nbsp;</li><li>If you have severe low blood pressure (hypotension)</li><li>If you suffer from heart failure after a heart attack&nbsp;</li><li>If you are having dialysis or any other type of blood filtration. Depending on the machine that is used, Pratima Duo may not be suitable for you</li><li>If you have kidney problems where the blood supply to your kidneys is reduced (renal artery stenosis)&nbsp;</li><li>If you have taken or are currently taking sacubitril/valsartan, a medicine for heart failure, as the risk of angioedema (rapid swelling under the skin in an area such as the throat) is increased (see &ldquo;Warnings and precautions&rdquo; and &ldquo;Other medicines and Pratima Duo&rdquo;).</li></ul><p><strong>Warnings and precautions </strong></p><p>If you have any of the following please talk to your doctor, pharmacist or nurse before taking Pratima Duo:</p><ul><li>Hypertrophic cardiomyopathy (cardiac muscle disease) or renal artery stenosis (narrowing of the artery which supplies the kidney with blood)</li><li>Heart failure &nbsp;</li><li>Severe increase in blood pressure (hypertensive crisis) &nbsp;</li><li>Any other heart problems</li><li>Liver problems</li><li>Kidney problems or if you are receiving dialysis</li><li>Abnormally increased levels of a hormone called aldosterone in your blood (primary aldosteronism) &nbsp;</li><li>Collagen vascular disease (disease of the connective tissue) such as systemic lupus erythematosus or scleroderma &nbsp;</li><li>Diabetes &nbsp;</li><li>If you are on a salt restricted diet or use salt substitutes which contain potassium (a well balanced potassium blood level is essential) &nbsp;</li><li>If you are elderly and your dose needs to be increased</li><li>If you are taking any of the following medicines used to treat high blood pressure: &nbsp;<ul><li>An &ldquo;angiotensin II receptor blocker&rdquo; (ARBs) (also known as sartans - for example valsartan, telmisartan, irbesartan), in particular if you have diabetes-related kidney problems. &nbsp;</li><li>Aliskiren.</li></ul></li></ul><p>Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals. &nbsp;</p><p>See also information under the heading &ldquo;Do not take Pratima Duo&rdquo;.</p><ul><li>Are taking any of the following medicines, the risk of angioedema is increased:<ul><li>Racecadotril (used to treat diarrhea) &nbsp;</li><li>Sirolimus, everolimus, temsirolimus and other drugs belonging to the class of so-called mTor inhibitors (used to avoid rejection of transplanted organs and for cancer) &nbsp;</li><li>Sacubitril (available as fixed dose combination with valsartan) used to treat long-term heart failure &nbsp;</li><li>Linagliptin, saxagliptin, sitagliptin, vildagliptin and other drugs belonging to the class of the also called gliptins (used to treat diabetes).</li></ul></li><li>Are of black origin since you may have a higher risk of angioedema and this medicine may be less effective in lowering your blood pressure than in non-black patients.</li></ul><p><em>Angioedema </em></p><p>Angioedema (a severe allergic reaction with swelling of the face, lips, tongue or throat with difficulty in swallowing or breathing) has been reported in patients treated with ACE inhibitors, including perindopril and amlodipine. This may occur at any time during treatment. If you develop such symptoms, you should stop taking Pratima Duo and see a doctor immediately. See also section 4. &nbsp;</p><p>You must tell your doctor if you think you are (or might become) pregnant. Pratima Duo is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).</p><p>When you are taking Pratima Duo, you should also inform your doctor or the medical staff if you:</p><ul><li>Are going to have a general anaesthetic and/or major surgery &nbsp;</li><li>Have recently suffered from diarrhoea or vomiting (being sick)</li><li>Are to undergo LDL apheresis (the removal of cholesterol from your blood by a machine) &nbsp;</li><li>Are going to have desensitisation treatment to reduce the effects of an allergy to bee or wasp stings.</li></ul><p><strong>Children and adolescents </strong></p><p>Pratima Duo is not recommended for use in children and adolescents.</p><p><strong>Other medicines and </strong><strong>Pratima Duo</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. &nbsp;</p><p><em>You should avoid Pratima Duo with: </em></p><ul><li>Lithium (used to treat mania or depression) &nbsp;</li><li>Estramustine (used in cancer therapy) &nbsp;</li><li>Potassium-sparing drugs (triamterene, amiloride), potassium supplements or potassium-containing salt substitutes, other drugs which can increase potassium in your body (such as heparin, a medicine used to thin blood to prevent clots; trimethoprim and co-trimoxazole also known as trimethoprim/sulfamethoxazole for infections caused by bacteria) &nbsp;</li><li>Potassium-sparing drugs used in the treatment of heart failure: eplerenone and spironolactone at doses between 12.5 mg to 50 mg by day.</li></ul><p>Treatment with Pratima Duo can be affected by other medicines. Your doctor may need to change your dose and/or to take other precautions. Make sure to tell your doctor if you are taking any of the following medicines as special care may be required:</p><ul><li>Other medicines for high blood pressure, including angiotensin II receptor blocker (ARB), aliskiren (see also information under the headings &ldquo;Do not take Pratima Duo&rdquo; and &ldquo;Warnings and precautions&rdquo;), or diuretics (medicines which increase the amount of urine produced by the kidneys)</li><li>Medicines, which are most often used to treat diarrhea (racecadotril) or avoid rejection of transplanted organs (sirolimus, everolimus, temsirolimus and other drugs belonging to the class of so-called mTor inhibitors). See section &ldquo;Warnings and precautions&rdquo; &nbsp;</li><li>Sacubitril/valsartan (used to treat long-term heart failure). See sections &ldquo;Do not take Pratima Duo&rdquo; and &ldquo;Warnings and precautions&rdquo;</li><li>Non-steroidal anti-inflammatory drugs (e.g. ibuprofen) for pain relief or high dose acetylsalicylic acid, a substance present in many medicines used to relieve pain and lower fever, as well as to prevent blood clotting &nbsp;</li><li>Medicines to treat diabetes (such as insulin) &nbsp;</li><li>Medicines to treat mental disorders such as depression, anxiety, schizophrenia etc (e.g. tricyclic antidepressants, antipsychotics, imipramine-like antidepressants, neuroleptics)</li><li>Immunosuppressants (medicines which reduce the defence mechanism of the body) used for the treatment of auto-immune disorders or following transplant surgery (e.g. ciclosporin, tacrolimus)</li><li>Trimethoprim and Co-trimoxazole (for the treatment of infections) &nbsp;</li><li>Allopurinol (for the treatment of gout)</li><li>Procainamide (for the treatment of an irregular heart beat)</li><li>Vasodilators including nitrates (products that widen the blood vessels) &nbsp;</li><li>Ephedrine, noradrenaline or adrenaline (medicines used to treat low blood pressure, shock or asthma)</li><li>Baclofen or dantrolene (infusion) both used to treat muscle stiffness in diseases such as multiple sclerosis; dantrolene is also used to treat malignant hyperthermia during anaesthesia (symptoms including very high fever and muscle stiffness)</li><li>Some antibiotics such as rifampicin, erythromycin, clarithromycin (for infection caused by bacteria)</li><li>Hypericum perforatum<em> </em>(St John&rsquo;s wort, an herbal medicine used to treat depression)</li><li>Simvastatin (cholesterol lowering medicine)</li><li>Antiepileptic agents such as carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone &nbsp;</li><li>Itraconazole, ketoconazole (medicines used for treatment of fungal infections)</li><li>Alpha-blockers used for the treatment of enlarged prostate such as prazosin, alfuzosin, doxazosin, tamsulosin, terazosin</li><li>Amifostine (used to prevent or reduce side effects caused by other medicines or radiation therapy that are used to treat cancer)</li><li>Corticosteroids (used to treat various conditions including severe asthma and rheumatoid arthritis)</li><li>Gold salts, especially with intravenous administration (used to treat symptoms of rheumatoid arthritis)</li><li>Ritonavir, indinavir, nelfinavir (so called protease inhibitors used to treat HIV).</li></ul><p><strong>Pratima Duo with food and drink</strong></p><p>Pratima Duo should be taken before a meal.</p><p>Grapefruit juice and grapefruit should not be consumed by people who are taking Pratima Duo. This is because grapefruit and grapefruit juice can lead to an increase in the blood levels of the active ingredient amlodipine, which can cause an unpredictable increase in the blood pressure lowering effect of Pratima Duo.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><em>Pregnancy </em></p><p>You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking Pratima Duo before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Pratima Duo. Pratima Duo is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.</p><p><em>Breast-feeding </em></p><p>Amlodipine has been shown to pass into breast milk in small amounts. Tell your doctor if you are breast-feeding or about to start breast-feeding. Pratima Duo is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.</p><p><strong>Driving and using machines </strong></p><p>Pratima Duo may affect your ability to drive or use machines. If the tablets make you feel sick, dizzy, weak or tired, or give you a headache, do not drive or use machines and contact your doctor immediately.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Swallow your tablet with a glass of water, preferably at the same time each day, in the morning, before a meal. Your doctor will decide on the correct dose for you. This will normally be one tablet per day.</p><p>Pratima Duo will usually be prescribed for patients already taking perindopril and amlodipine from separate tablets.</p><p><strong>Use in children and adolescents </strong></p><p>Use in children and adolescents is not recommended.</p><p><strong>If you take more Pratima Duo than you should</strong></p><p>If you take too many tablets, contact your nearest accident and emergency department or tell your doctor immediately. The most likely effect in case of overdose is low blood pressure which can make you feel dizzy or faint. If this happens, lying down with your legs raised can help.</p><p><strong>If you forget to take </strong><strong>Pratima Duo</strong></p><p>It is important to take your medicine every day as regular treatment works better. However, if you forget to take a dose of Pratima Duo, take the next dose at the usual time. Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking </strong><strong>Pratima Duo</strong></p><p>As the treatment with Pratima Duo is usually life-long, you should discuss with your doctor before you stop taking your tablets.</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>If you experience any of the following, stop taking the medicinal product at once and tell your doctor immediately: </strong></p><ul><li>Sudden wheeziness, chest pain, shortness of breath, or difficulty in breathing</li><li>Swelling of eyelids, face or lips &nbsp;</li><li>Swelling of the tongue and throat, which causes great difficulty breathing &nbsp;</li><li>Severe skin reactions including intense skin rash, hives, reddening of the skin over your whole body, severe itching, blistering, peeling and swelling of the skin, inflammation of mucous membranes (Stevens Johnson Syndrome, Toxic Epidermal Necrolysis) or other allergic reactions</li><li>Severe dizziness or fainting</li><li>Heart attack, unusual fast or abnormal heart beat, or chest pain</li><li>Inflamed pancreas which may cause severe abdominal and back pain accompanied with feeling very unwell.</li></ul><p><strong>The following common side effects have been reported. If any of these cause you problems or if they last for more than one week, you should contact your doctor. </strong></p><ul><li>Very common side effects (may affect more than 1 in 10 people): oedema (fluid retention)</li><li>Common side effects (may affect up to 1 in 10 people): headache, dizziness, sleepiness (especially at the beginning of treatment), vertigo, numbness or tingling sensation in your limbs, vision disturbances (including double vision), tinnitus (sensation of noises in the ears), palpitations (awareness of your heartbeat), flushing, light-headedness due to low blood pressure, cough, shortness of breath, nausea (feeling sick), vomiting (being sick), abdominal pain, taste disturbances, dyspepsia or difficulty of digestion, change of bowel habit, diarrhoea, constipation, allergic reactions (such as skin rashes, itching), muscle cramps, tiredness, weakness, ankle swelling (oedema peripheral).</li></ul><p><strong>Other side effects that have been reported include the following list. If any of these get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. </strong></p><ul><li>Uncommon side effects (may affect to 1 in 100 people): mood swings, anxiety, depression, sleeplessness, sleep disturbances, trembling, fainting, loss of pain sensation, irregular heart beat, rhinitis (blocked up or runny nose), hair loss, red patches on skin, skin discolouration, back pain, arthralgia (joint pain), myalgia (muscle pain), chest pain, disorder in passing urine, increased need to urinate at night, increased number of times of passing urine, pain, feeling unwell, bronchospasm (tightening of the chest, wheezing and shortness of breath), dry mouth, angioedema (symptoms such as wheezing, swelling of the face or tongue), formation of blister clusters over the skin, kidney problems, impotence, increased sweating, an excess of eosinophils (a type of white blood cells), discomfort or enlargement of the breasts in men, weight increase or decrease, tachycardia, vasculitis (inflammation of blood vessels), photosensitivity reaction (increased sensitivity of the skin to sun), fever, fall, change in laboratory parameters: high blood level of potassium reversible on discontinuation, low level of sodium, hypoglycaemia (very low blood sugar level) in case of diabetic patients, increased blood urea, and increased blood creatinine.</li><li>Rare side effects (may affect up to 1 in 1000 people): confusion, psoriasis worsening, changes in laboratory parameters: increased level of liver enzymes, high level of serum bilirubin.</li><li>Very rare side effects (may affect up to 1 in 10,000 people): cardiovascular disorders (angina, heart attack and stroke), eosinophilic pneumonia (a rare type of pneumonia), swelling of eyelids, face or lips, swelling of the tongue and throat, which causes great difficulty in breathing, severe skin reactions including intense skin rash, hives, reddening of the skin over your whole body, severe itching, blistering, peeling and swelling of the skin, inflammation of mucous membranes (Stevens Johnson Syndrome), erythema multiforme (a skin rash which often starts with red itchy patches on your face, arms or legs), sensitivity to light, changes in blood values such as a lower number of white and red blood cells, lower haemoglobin, lower number of blood platelets, disorders of the blood, inflamed pancreas which may cause severe abdominal and back pain accompanied with feeling very unwell, acute renal failure, abnormal liver function, inflammation of the liver (hepatitis), yellowing of the skin (jaundice), liver enzyme increase which may have an effect on some medical tests, abdominal bloating (gastritis), disorder of the nerves which can cause weakness, tingling or numbness, increased muscle tension, swelling of the gums, excess sugar in blood (hyperglycaemia),</li><li>Frequency not known (frequency cannot be estimated from the available data): trembling, rigid posture, mask-like face, slow movements and a shuffling, unbalanced walk, discoloration, numbness and pain in fingers or toes (Raynaud&rsquo;s phenomenon).</li></ul><p>Concentrated urine (dark in colour), feel or are sick, have muscle cramps, confusion and fits which may be due to inappropriate ADH (anti-diuretic hormone) secretion can occur with ACE inhibitors. If you have these symptoms contact your doctor as soon as possible</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not store above 30&deg;C.</p><p>Store in the original package in order to protect from moisture.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substances are perindopril arginine and amlodipine besylate.</p><p>Each tablet of Pratima Duo 5 mg/5 mg Tablets contains 5 mg perindopril arginine and 6.94 mg amlodipine besylate equivalent to 5 mg amlodipine. &nbsp;</p><p>Each tablet of Pratima Duo 5 mg/10 mg Tablets contains 5 mg perindopril arginine and 13.88 mg amlodipine besylate equivalent to 10 mg amlodipine. &nbsp;</p><p>Each tablet of Pratima Duo 10 mg/5 mg Tablets contains 10 mg perindopril arginine and 6.94 mg amlodipine besylate equivalent to 5 mg amlodipine. &nbsp;</p><p>Each tablet of Pratima Duo 10 mg/10 mg Tablets contains 10 mg perindopril arginine and 13.88 mg amlodipine besylate equivalent to 10 mg amlodipine.</p><p>The other ingredients are microcrystalline cellulose, colloidal silicone dioxide and magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Pratima Duo 5 mg/5 mg Tablets are white to off white round-shaped tablets debossed with “5/5” on one side and plain on the other side in aluminum/aluminum blisters.

Pratima Duo 5 mg/10 mg Tablets are white to off white oblong-shaped tablets debossed with “5/10” on one side and plain on the other side in aluminum/aluminum blisters.

Pratima Duo 10 mg/5 mg Tablets are white to off white round-shaped tablets debossed with “10/5” on one side and plain on the other side in aluminum/aluminum blisters. 

Pratima Duo 10 mg/10 mg Tablets are white to off white round-shaped tablets debossed with “10/10” on one side and plain on the other side in aluminum/aluminum blisters. 

Pack size: 30 Tablets. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder, Batch releaser and Bulk manufacturer </strong></p><p>Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. BOX 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p><ul><li>United Arab of Emirates</li></ul><p>Pharmacovigilance &amp; Medical Device Section</p><p>P.O. Box: 1853</p><p>Tel: 80011111</p><p>Email: pv@mohap.gov.ae</p><p>Drug Department</p><p>Ministry of Health &amp; Prevention</p><p>Duba</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 01/2024; version number Un1.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يُوصف براتيما ديو لعلاج ارتفاع ضغط الدم و/أو علاج مرض الشريان التاجي المستقر (حالة يتم فيها انخفاض أو انسداد تدفق الدم إلى القلب).&nbsp;</p><p dir="RTL">يمكن للمرضى الذين يتناولون بالفعل بيريندوبريل وأملوديبين من أقراص منفصلة تناول بدلاً من ذلك قرص واحد من براتيما ديو الذي يحتوي على المكونين معاً.&nbsp;</p><p dir="RTL">براتيما ديو هو مزيج يجمع بين المادتين الفعالتين بيريندوبريل وأملوديبين.</p><p dir="RTL">البيريندوبريل هو مثبط للإنزيم المحول للأنجيوتنسين. والأملوديبين من حاصرات الكالسيوم (ينتمي إلى فئة من الأدوية تسمى ثنائي هيدرو البيريدين). يعملان معاً على توسيع الأوعية الدموية وإرخائها حتى يتدفق الدم من خلالها بسهولة أكبر، ويُسهِّل على قلبك الحفاظ على معدل تدفق دم جيد.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول براتيما ديو </strong></p><ul dir="rtl"><li>إذا كنت تعاني من رد فعل تحسسي لبيريندوبريل أو أي مثبط آخر للإنزيم المحول للأنجيوتنسين، أو لأملوديبين أو أي من حاصرات الكالسيوم الأخرى، أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6)</li><li>إذا كنتِ حاملاً لأكثر من 3 أشهر (يُفضل أيضاً تجنب تناول دواء براتيما ديو في المراحل المبكرة من الحمل - انظري قسم الحمل)&nbsp;</li><li>إذا كنت قد عانيت من أعراض مثل الصفير، تورم الوجه أو اللسان، حكة شديدة أو طفح جلدي شديد عند علاجك سابقاً بمثبط للإنزيم المحول للأنجيوتنسين أو إذا سبق وأن عانيت أنت أو أحد أفراد عائلتك من هذه الأعراض في أي حالات أخرى (حالة تسمى الوذمة الوعائية)</li><li>إذا كنت تعاني من مرض السكري أو قصور في وظائف الكلى وتم علاجك بدواء خافض لضغط الدم يحتوي على أليسكيرين&nbsp;</li><li>إذا كنت تعاني من تضيق في صمام القلب الأبهري (تضيق الأبهر) أو صدمة قلبية (حالة يعجز فيها القلب على إمداد الجسم بالدم الكافي)&nbsp;</li><li>إذا كنت تعاني من انخفاض شديد في ضغط الدم (هبوط ضغط الدم)</li><li>إذا كنت تعاني من قصور في القلب بعد نوبة قلبية&nbsp;</li><li>إذا كنت تخضع لغسيل الكلى أو أي نوع آخر من ترشيح الدم. قد لا يكون دواء براتيما ديو مناسباً لك حسب الجهاز المستخدم&nbsp;</li><li>إذا كنت تعاني من مشاكل في الكلى حيث ينخفض تدفق الدم إلى كليتيك (تضيق الشريان الكلوي)&nbsp;</li><li>إذا كنت قد تناولت أو تتناول حالياً دواء ساكوبيتريل/فالسارتان، وهو دواء لعلاج قصور القلب، نظراً لزيادة خطر الإصابة بالوذمة الوعائية (تورم سريع تحت الجلد في منطقة مثل الحلق) (انظر &quot;الاحتياطات والتحذيرات&quot; و&quot;الأدوية الأخرى وبراتيما ديو&quot;).</li></ul><p dir="RTL"><strong>الاحتياطات والتحذيرات </strong></p><p dir="RTL">تحدث مع طبيبك، الصيدلي أو الممرض قبل تناول براتيما ديو إذا كنت تعاني من أي مما يلي:</p><ul dir="rtl"><li>اعتلال عضلة القلب الضخامي (مرض عضلة القلب) أو تضيق الشريان الكلوي (تضيق الشريان الذي يمد الكلى بالدم)</li><li>قصور القلب</li><li>ارتفاع شديد في ضغط الدم (نوبة فرط الضغط)&nbsp;</li><li>أي مشاكل قلبية أخرى&nbsp;</li><li>مشاكل في الكبد&nbsp;</li><li>مشاكل في الكلى أو إذا كنت تخضع لغسيل كلوي</li><li>زيادة غير طبيعية في مستويات هرمون يسمى الألدوستيرون في الدم (ألدوستيرونية أولية)&nbsp;</li><li>مرض الكولاجين الوعائي (مرض النسيج الضام) مثل الذئبة الحمامية المجموعية أو تصلب الجلد&nbsp;</li><li>داء السكري&nbsp;</li><li>إذا كنت تتبع نظاماً غذائياً قليل الملح أو تستخدم بدائل الملح التي تحتوي على البوتاسيوم (من الضروري أن يكون مستوى البوتاسيوم في الدم متوازناً)&nbsp;</li><li>إذا كنت مسناً وتحتاج إلى تناول جرعة أكبر</li><li>إذا كنت تتناول أياً من الأدوية التالية المستخدمة لعلاج ضغط الدم المرتفع:&nbsp;<ul><li>أحد &quot;حاصرات مستقبلات الأنجيوتنسين 2&quot; (تُسمى أيضاً بالسارتانات &nbsp;- مثل ڤالسارتان، تيلميسارتان، إربيسارتان)، لا سيما إذا كنت تعاني من مشاكل الكلى المرتبطة بالسكري.&nbsp;</li><li>أليسكيرين.</li></ul></li></ul><p dir="RTL">يمكن أن يتحقق طبيبك من وظائف الكلى لديك، ضغط دمك، وكمية الكهارل (على سبيل المثال البوتاسيوم) في دمك على فترات زمنية منتظمة.</p><p dir="RTL">انظر أيضاً المعلومات الموجودة تحت عنوان &quot;لا تتناول براتيما ديو&quot;.</p><ul dir="rtl"><li>يزداد خطر الإصابة بالوذمة الوعائية عند تناول أي من الأدوية التالية:<ul><li>راسيكادوتريل (يستخدم لعلاج الإسهال)&nbsp;</li><li>سيروليموس، ايڤيروليموس، تيمسيروليموس، والأدوية الأخرى المنتمية إلى الفئة التي يُطلق عليها مثبطات هدف الثدييات من الراباميسين (تُستخدم لتجنب رفض الأعضاء المزروعة ولعلاج السرطان)&nbsp;</li><li>ساكوبيتريل (متوفر كجرعة ثابتة مع ڤالسارتان) ويُستخدم لعلاج قصور القلب طويل الأمد</li><li>ليناجلبتين، ساكساجلبتين، سيتاجلبتين، ڤيلداجلبتين وغيرها من الأدوية التي تنتمي إلى الفئة المعروفة باسم الجلبتينات (تُستخدم في علاج مرض السكري).</li></ul></li><li>إذا كنت من أصل أسود لأنك قد تكون أكثر عرضة للإصابة بالوذمة الوعائية وقد يكون هذا الدواء أقل فعالية في خفض ضغط الدم لديك مقارنة بالمرضى غير السود.</li></ul><p dir="RTL"><em>الوذمة الوعائية </em></p><p dir="RTL">تم الإبلاغ عن وذمة وعائية (رد فعل تحسسي شديد مع تورم في الوجه، الشفتين، اللسان أو الحلق مع وجود صعوبة في البلع أو التنفس) في المرضى الذين تمت معالجتهم بمثبطات الإنزيم المحول للأنجيوتنسين، بما في ذلك بيريندوبريل وأملوديبين. قد يحدث هذا في أي وقت أثناء تلقي العلاج. إذا عانيت من مثل هذه الأعراض، يجب عليك التوقف عن تناول براتيما ديو وزيارة الطبيب على الفور. انظر أيضاً القسم 4.&nbsp;</p><p dir="RTL">يجب إبلاغ الطبيب إذا كنتِ تعتقدين أنكِ حامل (أو قد تصبحين حاملاً). لا يوصى باستخدام براتيما ديو في شهور الحمل الأولى، ويجب عدم تناوله إذا كنت حاملاً منذ أكثر من 3 أشهر، لأنه قد يسبب ضرراً بالغاً لجنينك عند استخدامه في هذه المرحلة (انظري قسم الحمل).</p><p dir="RTL">عند تناولك براتيما ديو، يجب عليك أيضاً إخبار طبيبك أو الطاقم الطبي:</p><ul dir="rtl"><li>إذا كنت ستخضع لتخدير عام وجراحة كبرى أو أحدهما&nbsp;</li><li>إذا عانيت مؤخراً من الإسهال أو القيء (الغثيان)&nbsp;</li><li>ستخضع لفصادة البروتين الدهني منخفض الكثافة (إزالة الكوليسترول من الدم بواسطة جهاز)&nbsp;</li><li>ستتلقى علاجاً لإزالة الحساسية لتقليل آثار الحساسية تجاه لسعات النحل أو الدبابير.</li></ul><p dir="RTL"><strong>الأطفال والمراهقون </strong></p><p dir="RTL">لا ينصح باستخدام براتيما ديو لدى الأطفال والمراهقين.</p><p dir="RTL"><strong>الأدوية الأخرى و</strong><strong>براتيما ديو</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، تناولت مؤخراً أو قد تتناول أية أدوية أخرى.&nbsp;</p><p dir="RTL"><em>يجب تجنب استخدام براتيما ديو مع: </em></p><ul dir="rtl"><li>الليثيوم (يُستخدم لعلاج الهوس أو الاكتئاب)&nbsp;</li><li>الإستراموستين (يُستخدم في علاج السرطان)&nbsp;</li><li>الأدوية الحافظة على البوتاسيوم (تريامتيرين، أميلوريد)، أو مكملات البوتاسيوم أو بدائل الملح المحتوية على البوتاسيوم، أو الأدوية الأخرى التي يمكن أن تزيد مستويات البوتاسيوم في الجسم (مثل الهيبارين، وهو دواء يستخدم لزيادة سيولة الدم لمنع تشكل الجلطات؛ تريميثوبريم وكوتريموكسازول المعروفان أيضاً باسم تريميثوبريم/سلفاميثوكسازول للعدوى التي تسببها البكتيريا)&nbsp;</li><li>الأدوية الحافظة على البوتاسيوم المستخدمة في علاج قصور القلب: إبليرينون وسبيرونولاكتون بجرعات تتراوح بين 12.5 ملغم إلى 5 ملغم يومياً.</li></ul><p dir="RTL">العلاج بدواء براتيما ديو يمكن أن يتأثر بالأدوية الأخرى. قد يحتاج طبيبك إلى تغيير جرعتك و/أو اتخاذ احتياطات أخرى. احرص على إخبار طبيبك إذا كنت تتناول أياً من الأدوية التالية، لأن الأمر قد يتطلب عناية خاصة:</p><ul dir="rtl"><li>أدوية أخرى لعلاج ارتفاع ضغط الدم، بما في ذلك حاصر مستقبلات الأنجيوتنسين 2، أليسكرين (انظر أيضاً المعلومات الموجودة تحت العنوانين &quot;لا تتناول براتيما ديو&quot; و&quot;الاحتياطات والتحذيرات&quot;)، أو مدرات البول (الأدوية التي تعمل على زيادة كمية البول التي تنتجها الكلى)&nbsp;</li><li>الأدوية التي تُستخدم غالباً لعلاج الإسهال (راسيكادوتريل) أو تجنب رفض الأعضاء المزروعة (سيروليموس، إيفروليموس، تيمسيروليموس والأدوية الأخرى المنتمية إلى الفئة التي يُطلق عليها مثبطات هدف الثدييات من الراباميسين. انظر قسم &quot;الاحتياطات والتحذيرات&quot;&nbsp;</li><li>ساكوبيتريل/ڤالسارتان (لعلاج قصور القلب طويل الأمد). انظر قسم &quot;لا تتناول براتيما ديو&quot; و&quot;الاحتياطات والتحذيرات&quot;&nbsp;</li><li>مضادات الالتهاب غير الستيرويدية (مثل الإيبوبروفين) لتسكين الآلام أو جرعة عالية من حمض أسيتيل الساليسيليك، وهي مادة موجودة في العديد من الأدوية المستخدمة لتسكين الألم وخفض الحمى إضافة إلى منع تخثر الدم&nbsp;</li><li>أدوية لعلاج مرض السكري (مثل الأنسولين)&nbsp;</li><li>أدوية لعلاج الاضطرابات النفسية مثل الاكتئاب، القلق، الفصام العقلي، وما إلى ذلك (مثل مضادات الاكتئاب ثلاثية الحلقات، مضادات الذهان، مضادات الاكتئاب المماثلة للإيميبرامين، مهدئات الأعصاب)</li><li>الأدوية المثبطة للمناعة (الأدوية التي تقلل آلية الدفاع عن الجسم) المستخدمة لعلاج اضطرابات المناعة الذاتية أو ما يعقب جراحة الزرع (مثل سيكلوسبورين، تاكروليموس)</li><li>تريميثوبريم وكوتريموكسازول (لعلاج الالتهابات)&nbsp;</li><li>ألوبورينول (لعلاج النقرس)</li><li>بروكاييناميد (لعلاج عدم انتظام ضربات القلب)&nbsp;</li><li>موسعات الأوعية الدموية بما في ذلك النترات (الأدوية التي توسع الأوعية الدموية)&nbsp;</li><li>الإيفيدرين، النورأدرينالين أو الأدرينالين (الأدوية المستخدمة لعلاج انخفاض ضغط الدم، الصدمة أو الربو)</li><li>باكلوفين أو دانترولين (بالتسريب)، ويُستخدم كلاهما لعلاج تيبس العضلات المصاحب لأمراض مثل التصلب المتعدد؛ ويُستخدم دانترولين أيضاً لعلاج فرط الحرارة الخبيث أثناء التخدير (تشمل الأعراض الحمى الشديدة جداً وتيبس العضلات)</li><li>بعض المضادات الحيوية مثل ريفامبيسين، إريثروميسين، كلاريثروميسين (لعلاج العدوى التي تسببها البكتيريا)</li><li>عشبة العرن<em> </em>(نبتة سانت جونز، منتج عشبي يُستخدم لعلاج الاكتئاب)</li><li>سيمڤاستاتين (دواء لخفض الكوليسترول)</li><li>مضادات الصرع مثل كاربامازيبين، فينوباربيتال، فينتوين، فوسفينتوين، بريميدون&nbsp;</li><li>إيتراكونازول، كيتوكونازول (أدوية تستخدم لعلاج الالتهابات الفطرية)</li><li>حاصرات ألفا المستخدمة لعلاج تضخم البروستاتا مثل برازوسين، الفوزوسين، دوكسازوسين، تامسولوسين، تيرازوسين</li><li>أميفوستين (يُستخدم لمنع أو تقليل الآثار الجانبية التي تسببها الأدوية الأخرى أو العلاج الإشعاعي الذي يستخدم لعلاج السرطان)</li><li>االستيرويدات القشرية (تُستخدم في علاج حالات مختلفة منها الربو الشديد والتهاب المفاصل الروماتويدي)</li><li>أملاح الذهب، خاصةً التي تؤخذ عن طريق الحقن الوريدي (تُستخدم لعلاج أعراض التهاب المفاصل الروماتويدي)</li><li>ريتوناڤير، إنديناڤير، نيلفيناڤير (تُسمى مثبطات البروتياز وتُستخدم لعلاج فيروس العوز المناعي البشري).</li></ul><p dir="RTL"><strong>براتيما ديو مع الطعام والشراب</strong></p><p dir="RTL">يجب تناول براتيما ديو قبل وجبة الطعام.</p><p dir="RTL">يجب على الأشخاص الذين يتناولون براتيما ديو عدم تناول عصير الجريب فروت والجريب فروت. وذلك لأن الجريب فروت وعصير الجريب فروت يمكن أن يؤديا إلى زيادة مادة أملوديبين الفعالة في مستويات الدم، مما قد يحدث زيادة غير متوقعة في تأثير خفض ضغط الدم بفعل براتيما ديو.</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">اطلبي النصيحة من طبيبك أو الصيدلي قبل تناول هذا الدواء إذا كنت حاملاً أو مرضعاً، تعتقدين بأنك حاملاً أو تخططين لذلك.</p><p dir="RTL"><em>الحمل </em></p><p dir="RTL">يجب إبلاغ الطبيب إذا كنتِ تعتقدين أنكِ حامل (أو قد تصبحين حاملاً). سينصحك طبيبك عادة بالتوقف عن تناول براتيما ديو قبل أن تصبحي حاملاً أو بمجرد معرفتك بأنك حامل، وسينصحك بتناول دواء آخر بدلاً من براتيما ديو. لا يوصى باستخدام براتيما ديو في شهور الحمل الأولى، ويجب عدم تناوله إذا كنت حاملاً منذ أكثر من 3 أشهر، لأنه قد يسبب ضرراً بالغاً لجنينك عند استخدامه بعد الشهر الثالث من الحمل.</p><p dir="RTL"><em>الرضاعة </em></p><p dir="RTL">ثبت أن أملوديبين ينتقل إلى حليب الثدي بكميات صغيرة. أخبري طبيبك إذا كنت مرضعاً أو إذا كنت على وشك البدء بالرضاعة. لا يوصى باستخدام براتيما ديو للأمهات اللواتي يرضعن رضاعة طبيعية، وقد يختار طبيبك علاجاً آخر لك إذا كنتِ ترغبين في تقديم الرضاعة الطبيعية، وخاصةً إذا كان طفلك حديث الولادة أو كان مولوداً قبل موعد ولادته.</p><p dir="RTL"><strong>القيادة واستخدام الآلات </strong></p><p dir="RTL">قد يؤثر براتيما ديو على قدرتك على القيادة أو استخدام الآلات. إذا كانت الأقراص تجعلك تشعر بالغثيان، الدوار، الضعف أو التعب، أو تسبب لك الصداع، فامتنع عن القيادة أو استخدام الآلات واتصل بطبيبك على الفور</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قم دائماً بتناول دوائك كما أخبرك طبيبك أو الصيدلي تماماً. تحقق من طبيبك أو الصيدلي إذا لم تكن متأكداً.</p><p dir="RTL">ابتلع القرص مع كوب من الماء، ويفضل في نفس الوقت كل يوم، في الصباح، قبل وجبة الطعام. سيقرر طبيبك الجرعة المناسبة لك. ستكون الجرعة عادةً قرص واحد يومياً.</p><p dir="RTL">وعادةً ما يوصف براتيما ديو للمرضى الذين يتناولون بالفعل بيريندوبريل وأملوديبين من أقراص منفصلة.</p><p dir="RTL"><strong>الاستخدام لدى الأطفال والمراهقين </strong></p><p dir="RTL">لا ينصح باستخدامه لدى الأطفال والمراهقين.</p><p dir="RTL"><strong>إذا تناولت براتيما ديو أكثر من اللازم</strong></p><p dir="RTL">إذا تناولت عدداً كبيراً من الأقراص، فاتصل بأقرب قسم للطوارئ والحوادث أو أخبر طبيبك على الفور. من المرجح أن يتمثل التأثير في حالة الجرعة الزائدة في انخفاض ضغط الدم الذي قد يجعلك تشعر بالدوار أو الإغماء. إذا حدث ذلك، يمكن أن يساعدك الاستلقاء مع رفع ساقيك.</p><p dir="RTL"><strong>إذا نسيت تناول براتيما ديو</strong></p><p dir="RTL">من المهم تناول الدواء كل يوم، حيث إن تناول العلاج بانتظام يعطي نتيجة أفضل. ومع ذلك، إذا نسيت تناول جرعة من براتيما ديو، فتناول الجرعة التالية في الوقت المعتاد. لا تقم بتناول جرعة مضاعفة لتعويض الجرعة المنسية.</p><p dir="RTL"><strong>إذا توقفت عن تناول </strong><strong>براتيما ديو</strong></p><p dir="RTL">نظراً لأن العلاج باستخدام براتيما ديو يستمر عادةً مدى الحياة، يجب عليك مناقشة طبيبك قبل التوقف عن تناول الأقراص.</p><p dir="RTL">إذا كان لديك أي أسئلة إضافية حول استخدام هذا الدواء، اسأل الطبيب، الصيدلي أو الممرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبية إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا واجهت أياً مما يلي، فتوقف عن تناول المستحضر الدوائي فوراً وأخبر طبيبك على الفور: </strong></p><ul dir="rtl"><li>صفير مفاجئ، ألم في الصدر، ضيق في التنفس، أو صعوبة في التنفس</li><li>تورم الجفون، الوجه أو الشفتين&nbsp;</li><li>تورم اللسان والحلق مما يسبب صعوبة كبيرة في التنفس&nbsp;</li><li>ردود فعل جلدية شديدة بما في ذلك الطفح الجلدي الشديد، الشرى، احمرار الجلد في جميع أنحاء الجسم، الحكة الشديدة، التبثر، تقشير وتورم الجلد، التهاب الأغشية المخاطية (متلازمة ستيفنز جونسون، تقشر الأنسجة المتموتة البشروية التسممي) أو ردود الفعل التحسسية الأخرى</li><li>دوار شديد أو إغماء</li><li>أزمة قلبية، ضربات قلب سريعة أو غير طبيعية، أو ألم في الصدر</li><li>التهاب البنكرياس الذي قد يسبب آلاماً شديدة في البطن والظهر مصحوبة بالشعور بتوعك شديد.</li></ul><p dir="RTL"><strong>تم الإبلاغ عن الآثار الجانبية الشائعة التالية. إذا تسبب لك أي منها في مشكلات أو إذا استمر لأكثر من أسبوع، يجب عليك الاتصال بطبيبك. </strong></p><ul dir="rtl"><li>آثار جانبية شائعة جداً (قد تؤثر في أكثر من شخص من بين كل 10 أشخاص): وذمة (احتباس السوائل)</li><li>آثار جانبية شائعة (قد تؤثر فيما يصل إلى شخص من بين كل 10 أشخاص): صداع، دوار، نعاس (خاصة في بداية العلاج)، دوخة، تنميل أو إحساس بالوخز في أطرافك، اضطرابات في الرؤية (بما في ذلك الرؤية المزدوجة)، طنين (الشعور بضوضاء في الأذنين)، خفقان (الإحساس بضربات القلب)، احمرار الوجه، الدوار بسبب انخفاض ضغط الدم، سعال، ضيق التنفس، غثيان (الشعور بالإعياء)، قيء (الشعور بالغثيان)، ألم في البطن، اضطرابات في التذوق، عسر الهضم أو صعوبة الهضم، تغير في عادات التبرز، إسهال، إمساك، ردود فعل تحسسية (مثل طفح جلدي، حكة)، تشنجات عضلية، إرهاق، ضعف، تورم الكاحل (وذمة طرفية).</li></ul><p dir="RTL"><strong>تشمل الآثار الجانبية الأخرى التي تم الإبلاغ عنها القائمة التالية. يرجى إخبار الطبيب، أو الصيدلي في حال أصبحت أي من الآثار الجانبية &nbsp;خطيرة، أو في حال ظهور أية آثار جانبية لم تذكر في هذه النشرة.</strong></p><ul dir="rtl"><li>آثار جانبية غير شائعة (قد تؤثر فيما يصل إلى شخص من بين كل 100 شخص): تقلبات مزاجية، قلق، اكتئاب، أرق، اضطرابات في النوم، ارتعاش، إغماء، فقدان الإحساس بالألم، عدم انتظام ضربات القلب، التهاب الأنف (انسداد أو سيلان الأنف)، تساقط الشعر، بقع حمراء على الجلد، تغير لون الجلد، ألم بالظهر، ألم مفصلي، ألم عضلي، ألم في الصدر، اضطراب في التبول، زيادة الحاجة إلى التبول ليلاً، زيادة عدد مرات التبول، ألم، شعور بالتوعك، التشنج القصبي (ضيق في الصدر، صفير وضيق في التنفس)، جفاف الفم، وذمة وعائية (أعراض مثل الصفير، تورم الوجه أو اللسان)، تكوُّن مجموعة تقرحات على الجلد، مشاكل في الكُلى، الضعف الجنسي، زيادة التعرق، زيادة في اليوزينيات (نوع من خلايا الدم البيضاء)، عدم الراحة أو تضخم الثديين عند الرجال، زيادة الوزن أو نقصانه، تسرع القلب، الالتهاب الوعائي (التهاب الأوعية الدموية)، رد فعل تحسسي للضوء (زيادة حساسية الجلد للشمس)، حمّى، سقوط، تغيير في مؤشرات المختبر: ارتفاع مستوى البوتاسيوم في الدم الذي ينعكس عند التوقف، انخفاض مستوى الصوديوم، نقص سكر الدم (انخفاض شديد في مستوى السكر في الدم) في حالة مرضى السكري، زيادة اليوريا في الدم، زيادة الكرياتينين في الدم.</li><li>آثار جانبية نادرة (قد تؤثر فيما يصل إلى شخص من بين كل 1000 شخص): ارتباك، تدهور الصدفية، تغيرات في مؤشرات المختبر: زيادة مستوى إنزيمات الكبد، ارتفاع مستوى بيليروبين الدم.</li><li>آثار جانبية نادرة جداً (قد تؤثر فيما يصل إلى شخص من بين كل 10000 شخص): اضطرابات القلب والأوعية الدموية (الذبحة الصدرية، الأزمة القلبية، السكتة الدماغية)، الالتهاب الرئوي اليوزيني (نوع نادر من الالتهاب الرئوي)، تورم الجفون، الوجه أو الشفتين، تورم اللسان والحلق، مما يسبب صعوبة كبيرة في التنفس، ردود فعل جلدية شديدة بما في ذلك طفح جلدي شديد والشرى الجلدي واحمرار الجلد في جميع أنحاء الجسم، الحكة الشديدة، التبثر، تقشير وتورم الجلد، التهاب الأغشية المخاطية (متلازمة ستيفنز جونسون)، الحمامى عديدة الأشكال (طفح جلدي يبدأ عادةً ببقع حمراء مثيرة للحكة على وجهك أو ذراعيك أو ساقيك)، حساسية للضوء، تغيرات في قيم الدم مثل انخفاض عدد خلايا الدم البيضاء والحمراء، انخفاض مستوى الهيموجلوبين، انخفاض عدد الصفيحات الدموية، اضطرابات الدم، التهاب البنكرياس الذي قد يسبب آلاماً شديدة في البطن والظهر مصحوبة بالشعور بتوعك شديد، فشل كلوي حاد، اختلال وظائف الكبد، التهاب الكبد (الالتهاب الكبدي)، اصفرار الجلد (اليرقان)، زيادة إنزيمات الكبد والتي قد يكون لها تأثير على بعض الفحوصات الطبية، انتفاخ البطن (التهاب المعدة)، اضطراب في الأعصاب يمكن أن يسبب الضعف، الوخز أو التنميل، زيادة تشنج العضلات، تورم اللثة، زيادة مستوى السكر في الدم (ارتفاع مستوى السكر في الدم)،</li><li>تكرار غير معروف (لا يمكن تقدير التكرار من البيانات المتاحة): ارتعاش، وضعية متصلبة، وجه يشبه القناع، حركات بطيئة ومشي متثاقل، مشي غير متوازن، تغير في اللون، تنميل وألم في أصابع اليدين أو القدمين (ظاهرة رينو).</li></ul><p dir="RTL">البول المركّز (داكن اللون)، الشعور بالغثيان أو المرض، الإصابة بتقلصات عضلية، ارتباك ونوبات قد تحدث بسبب الإفراز اللامتناسب للهرمون المضاد لإدرار البول الذي يمكن أن يحدث مع مثبطات الإنزيم المحول للأنجيوتنسين. إذا كانت لديك هذه الأعراض، فاتصل بطبيبك في أقرب وقت ممكن</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا يحفظ عند درجة حرارة أعلى من 30&deg;&nbsp;مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية للحماية من الرطوبة.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &quot;EXP&quot;. يشير تاريخ الانتهاء إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المواد الفعالة هي بيريندوبريل أرجينين وأملوديبين بيسيلات.</p><p dir="RTL">يحتوي كل قرص من براتيما ديو 5 ملغم/5 ملغم أقراص على 5 ملغم بيريندوبريل أرجينين و6.94 ملغم أملوديبين بيسيلات يكافئ 5 ملغم أملوديبين.&nbsp;</p><p dir="RTL">يحتوي كل قرص من براتيما ديو 5 ملغم/10 ملغم أقراص على 5 ملغم بيريندوبريل أرجينين و13.88 ملغم أملوديبين بيسيلات يكافئ 10 ملغم أملوديبين.&nbsp;</p><p dir="RTL">يحتوي كل قرص من براتيما ديو 10 ملغم/5 ملغم أقراص على 10 ملغم بيريندوبريل أرجينين و6.94 ملغم أملوديبين بيسيلات يكافئ 5 ملغم أملوديبين.&nbsp;</p><p dir="RTL">يحتوي كل قرص من براتيما ديو 10 ملغم/10 ملغم أقراص على 10 ملغم بيريندوبريل أرجينين و13.88 ملغم أملوديبين بيسيلات يكافئ 10 ملغم أملوديبين.&nbsp;</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي سيلليلوز بلوري مكروي، ثاني أكسيد السيليكون الغروي وستيرات المغنيسيوم.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">براتيما ديو 5 ملغم/ 5 ملغم أقراص هي أقراص لونها أبيض إلى أبيض مائل للصفرة دائرية الشكل محفور &quot;5/5&quot; على أحد جانبيها وفارغة على الجانب الآخر في أشرطة من الألومنيوم/الألومنيوم.</p><p dir="RTL">أقراص براتيما ديو 5 ملغم/ 10 ملغم هي أقراص لونها أبيض إلى أبيض مائل للصفرة مستطيلة الشكل محفور &quot;5/10&quot; على أحد جانبيها وفارغة على الجانب الأخر في أشرطة من الألومنيوم/الألومنيوم.</p><p dir="RTL">براتيما ديو 10 ملغم/ 5 ملغم أقراص هي أقراص لونها أبيض إلى أبيض مائل للصفرة دائرية الشكل محفور &quot;10/5&quot; &nbsp;على أحد جانبيها وفارغة على الجانب الآخر في أشرطة من الألومنيوم/الألومنيوم.</p><p dir="RTL">براتيما ديو 10 ملغم/ 10 ملغم أقراص هي أقراص لونها أبيض إلى أبيض مائل للصفرة دائرية الشكل محفور &quot;10/10&quot; على أحد جانبيها وفارغة على الجانب الآخر في أشرطة من الألومنيوم/الألومنيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اسم وعنوان مالك رخصة التسويق، محرر التشغيلة والشركة المصنعة للمستحضر النهائي </strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com<br />&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية، وذلك يشمل أية آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><ul dir="rtl"><li>المملكة العربية السعودية</li></ul><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><ul dir="rtl"><li>دول الخليج العربي الأخرى</li></ul><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p><ul dir="rtl"><li>الإمارات العربية المتحدة</li></ul><p dir="RTL">قسم اليقظة الدوائية والجهاز الطبي</p><p dir="RTL">صندوق بريد: 1853</p><p dir="RTL">هاتف: 80011111</p><p dir="RTL">البريد الإلكتروني: pv@mohap.gov.ae</p><p dir="RTL">إدارة الدواء</p><p dir="RTL">وزارة الصحة ووقاية المجتمع</p><p dir="RTL">دبي</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 01/2024؛ رقم النسخة Un1.0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pratima Duo 5 mg/10 mg Tablets 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 5 mg perindopril arginine and 13.88 amlodipine besylate equivalent to 10 mg amlodipine.  

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets. 

White to off white oblong-shaped tablets debossed with “5/10” on one side and plain on other side. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pratima Duo is indicated as substitution therapy for treatment of essential hypertension and/or stable coronary artery disease, in patients already controlled with perindopril and amlodipine given concurrently at the same dose level.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong></p><p>Oral route.</p><p>One tablet per day as a single dose, preferably to be taken in the morning and before a meal.</p><p>The fixed dose combination is not suitable for initial therapy.</p><p>If a change of posology is required, the dose of Pratima Duo could be modified or individual titration with free combination may be considered.</p><p><u>&nbsp;Special populations </u></p><p><em>Renal impairment and elderly (see sections 4.4 and 5.2) </em></p><p>Elimination of perindoprilat is decreased in the elderly and in patients with renal failure. Therefore, the usual medical follow-up will include frequent monitoring of creatinine and potassium.</p><p>Pratima Duo can be administered in patients with Clcr &ge; 60 ml/min, and is not suitable for patients with Clcr &lt; 60 ml/min. In these patients, an individual dose titration with the monocomponents is recommended.</p><p>Amlodipine used at similar doses in elderly or younger patients is equally well tolerated. Normal dosage regimens are recommended in the elderly, but increase of the dosage should take place with care. Changes in amlodipine plasma concentrations are not correlated with degree of renal impairment. Amlodipine is not dialysable.</p><p><em>Hepatic impairment: see sections 4.4 and 5.2 </em></p><p>Dosage recommendations have not been established in patients with mild to moderate hepatic impairment; therefore dose selection should be cautious and should start at the lower end of the dosing range (see sections 4.4 and 5.2). To find the optimal starting dose and maintenance dose of patients with hepatic impairment, the patients should be individually titrated using the free combination of amlodipine and perindopril. The pharmacokinetics of amlodipine have not been studied in severe hepatic impairment. Amlodipine should be initiated at the lowest dose and titrated slowly in patients with severe hepatic impairment.</p><p><em>Paediatric population </em></p><p>Pratima Duo should not be used in children and adolescents as the efficacy and tolerability of perindopril and amlodipine, in combination, have not been established in children and adolescents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Linked to perindopril: 
•	Hypersensitivity to the active substance or to any other ACE inhibitor,  
•	History of angioedema associated with previous ACE inhibitor therapy,  
•	Hereditary or idiopathic angioedema,  
•	Second and third trimesters of pregnancy (see sections 4.4 and 4.6),  
•	Concomitant use of Pratima Duo with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m²) (see sections 4.5 and 5.1). 
•	Concomitant use with sacubitril/valsartan therapy. Pratima Duo must not be initiated earlier than 36 hours after the last dose of sacubitril/valsartan (see sections 4.4 and 4.5). 
•	Extracorporeal treatments leading to contact of blood with negatively charged surfaces (see section 4.5), 
•	Significant bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney (see section 4.4). 

Linked to amlodipine: 
•	Severe hypotension,  
•	Hypersensitivity to the active substance or to dihydropyridines derivatives,  
•	Shock, including cardiogenic shock,  
•	Obstruction of the outflow-tract of the left ventricle (e.g. high grade aortic stenosis), 
•	Haemodynamically unstable heart failure after acute myocardial infarction. 

Linked to Pratima Duo: 
All contraindications related to each monocomponent, as listed above, should apply also to the fixed combination of Pratima Duo. 
•	Hypersensitivity to any of the excipients listed in section 6.1. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>All warnings related to each monocomponent, as listed below, should apply also to the fixed combination of Pratima Duo.</p><p><strong>Linked to perindopril</strong></p><p><u>Special warnings</u></p><p><em>Hypersensitivity/Angioedema:</em></p><p>Angioedema of the face, extremities, lips, mucous membranes, tongue, glottis and/or larynx has been reported rarely in patients treated with ACE inhibitors, including perindopril (see section 4.8). This may occur at any time during therapy. In such cases, Pratima Duo should promptly be discontinued and appropriate monitoring should be initiated and continued until complete resolution of symptoms has occurred. In those instances where swelling was confined to the face and lips the condition generally resolved without treatment, although antihistamines have been useful in relieving symptoms.</p><p>Angioedema associated with laryngeal oedema may be fatal. Where there is involvement of the tongue, glottis or larynx, likely to cause airway obstruction, emergency therapy should be administered promptly. This may include the administration of adrenaline and/or the maintenance of a patent airway. The patient should be under close medical supervision until complete and sustained resolution of symptoms has occurred.</p><p>Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor (see section 4.3).</p><p>Intestinal angioedema has been reported rarely in patients treated with ACE inhibitors. These patients presented with abdominal pain (with or without nausea or vomiting); in some cases there was no prior facial angioedema and C-1 esterase levels were normal. The angioedema was diagnosed by procedures including abdominal CT scan, or ultrasound or at surgery and symptoms resolved after stopping the ACE inhibitor. Intestinal angioedema should be included in the differential diagnosis of patients on ACE inhibitors presenting with abdominal pain (see section 4.8).</p><p>The combination of perindopril with sacubitril/valsartan is contraindicated due to the increased risk of angioedema (see section 4.3). Sacubitril/valsartan must not be initiated until 36 hours after taking the last dose of perindopril therapy. If treatment with sacubitril/valsartan is stopped, perindopril therapy must not be initiated until 36 hours after the last dose of sacubitril/valsartan (see sections 4.3 and 4.5). Concomitant use of ACE inhibitors with NEP inhibitors (e.g. racecadotril), mTOR inhibitors (e.g. sirolimus, everolimus, temsirolimus) and gliptins (e.g. linagliptin, saxagliptin, sitagliptin, vildagliptin) may lead to an increased risk of angioedema (e.g. swelling of the airways or tongue, with or without respiratory impairment) (see section 4.5). Caution should be used when starting racecadotril, mTOR inhibitors (e.g. sirolimus, everolimus, temsirolimus) and gliptins (e.g. linagliptin, saxagliptin, sitagliptin, vildagliptin) in a patient already taking an ACE inhibitor.</p><p><em>Anaphylactoid reactions during low-density lipoproteins (LDL) apheresis:</em></p><p>Rarely, patients receiving ACE inhibitors during low-density lipoprotein (LDL) apheresis with dextran sulphate have experienced life-threatening anaphylactoid reactions. These reactions were avoided by temporarily withholding ACE inhibitor therapy prior to each apheresis.</p><p><em>Anaphylactoid reactions during desensitisation:</em></p><p>Patients receiving ACE inhibitors during desensitisation treatment (e.g. hymenoptera venom) have experienced anaphylactoid reactions. In the same patients, these reactions have been avoided when the ACE inhibitors were temporarily withheld, but they reappeared upon inadvertent rechallenge.</p><p><em>Neutropenia/Agranulocytosis/Thrombocytopenia/Anaemia:</em></p><p>Neutropenia/agranulocytosis, thrombocytopenia and anaemia have been reported in patients receiving ACE inhibitors. In patients with normal renal function and no other complicating factors, neutropenia occurs rarely.</p><p>Perindopril should be used with extreme caution in patients with collagen vascular disease, immunosuppressant therapy, treatment with allopurinol or procainamide, or a combination of these complicating factors, especially if there is pre-existing impaired renal function. Some of these patients developed serious infections, which in a few instances did not respond to intensive antibiotic therapy. If perindopril is used in such patients, periodic monitoring of white blood cell counts is advised and patients should be instructed to report any sign of infection (e.g. sore throat, fever).</p><p><em>Renovascular hypertension:</em></p><p>There is an increased risk of hypotension and renal insufficiency when patient with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with ACE inhibitors (see section 4.3). Treatment with diuretics may be a contributory factor. Loss of renal function may occur with only minor changes in serum creatinine even in patients with unilateral renal artery stenosis.</p><p><em>Dual blockade of the renin-angiotensin-aldosterone system (RAAS):</em></p><p>There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).</p><p>If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.</p><p>ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</p><p><em>Primary aldosteronism:</em></p><p>Patients with primary hyperaldosteronism generally will not respond to anti-hypertensive drugs acting through inhibition of the renin-angiotensin system. Therefore, the use of this product is not recommended.</p><p><em>Pregnancy:</em></p><p>ACE inhibitors should not be initiated during pregnancy. Unless continued ACE inhibitors is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</p><p><u>Precautions for use</u></p><p><em>Hypotension:</em></p><p>ACE inhibitors may cause a fall in blood pressure. Symptomatic hypotension is seen rarely in uncomplicated hypertensive patients and is more likely to occur in patients who have been volume-depleted e.g. by diuretic therapy, dietary salt restriction, dialysis, diarrhoea or vomiting, or who have severe renin-dependent hypertension (see sections 4.5 and 4.8). In patients at high risk of symptomatic hypotension, blood pressure, renal function and serum potassium should be monitored closely during treatment with Pratima Duo.</p><p>Similar considerations apply to patients with ischaemic heart or cerebrovascular disease in whom an excessive fall in blood pressure could result in a myocardial infarction or cerebrovascular accident.</p><p>If hypotension occurs, the patient should be placed in the supine position and, if necessary, should receive an intravenous infusion of sodium chloride 9 mg/ml (0.9%) solution. A transient hypotensive response is not a contraindication to further doses, which can be given usually without difficulty once the blood pressure has increased after volume expansion.</p><p><em>Aortic and mitral valve stenosis / hypertrophic cardiomyopathy:</em></p><p>As with other ACE inhibitors, perindopril should be given with caution to patients with mitral valve stenosis and obstruction in the outflow of the left ventricle such as aortic stenosis or hypertrophic cardiomyopathy.</p><p><em>Renal impairement:</em></p><p>In cases of renal impairment (creatinine clearance &lt; 60 ml/min) an individual dose titration with the monocomponents is recommended (see section 4.2).</p><p>Routine monitoring of potassium and creatinine are part of normal medical practice for patients with renal impairment (see section 4.8).</p><p>In some patients with bilateral renal artery stenosis or stenosis of the artery to a solitary kidney, who have been treated with ACE inhibitors, increases in blood urea and serum creatinine, usually reversible upon discontinuation of therapy, have been seen. This is especially likely in patients with renal insufficiency. If renovascular hypertension is also present there is an increased risk of severe hypotension and renal insufficiency. Some hypertensive patients with no apparent pre-existing renal vascular disease have developed increases in blood urea and serum creatinine, usually minor and transient, especially when perindopril has been given concomitantly with a diuretic. This is more likely to occur in patients with pre-existing renal impairment.</p><p><em>Hepatic failure:</em></p><p>Rarely, ACE inhibitors have been associated with a syndrome that starts with cholestatic jaundice and progresses to fulminant hepatic necrosis and (sometimes) death. The mechanism of this syndrome is not understood. Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up (see section 4.8).</p><p><em>Race:</em></p><p>ACE inhibitors cause a higher rate of angioedema in black patients than in non-black patients.</p><p>As with other ACE inhibitors, perindopril may be less effective in lowering blood pressure in black people than in non-blacks, possibly because of a higher prevalence of low-renin states in the black hypertensive population.</p><p><em>Cough:</em></p><p>Cough has been reported with the use of ACE inhibitors. Characteristically, the cough is non-productive, persistent and resolves after discontinuation of therapy. ACE inhibitor-induced cough should be considered as part of the differential diagnosis of cough.</p><p><em>Surgery/Anaesthesia:</em></p><p>In patients undergoing major surgery or during anaesthesia with agents that produce hypotension, Pratima Duo may block angiotensin II formation secondary to compensatory renin release. The treatment should be discontinued one day prior to the surgery. If hypotension occurs and is considered to be due to this mechanism, it can be corrected by volume expansion.</p><p><em>Hyperkaliemia:</em></p><p>Elevations in serum potassium have been observed in some patients treated with ACE inhibitors, including perindopril, ACE inhibitors can cause hyperkalaemia because they inhibit the release of aldosterone. The effect is usually not significant in patients with normal renal function. Risk factors for the development of hyperkalemia include those with renal insufficiency, worsening of renal function, age (&gt; 70 years), diabetes mellitus, intercurrent events, in particular dehydratation, acute cardiac decompensation, metabolic acidosis, and concomitant use of potassium-sparing diuretics (e.g. spironolactone, eplerenone, triamterene, or amiloride), potassium supplements or potassium-containing salt substitutes; or those patients taking other drugs associated with increases in serum potassium (e.g. heparin, co-trimoxazole also known as trimethoprim/sulfamethoxazole) and especially aldosterone antagonists or angiotensin-receptor blockers. The use of potassium supplements, potassium-sparing diuretics, or potassium-containing salt substitutes particularly in patients with impaired renal function may lead to a significant increase in serum potassium. Hyperkalemia can cause serious, sometimes fatal arrhythmias. Potassium-sparing diuretics and angiotensin-receptor blockers should be used with caution in patients receiving ACE inhibitors, and serum potassium and renal function should be monitored.</p><p>If concomitant use of perindopril and any of the above mentioned agents is deemed appropriate, they should be used with caution and with frequent monitoring of serum potassium (see section 4.5).</p><p><em>Diabetic patients:</em></p><p>In diabetic patients treated with oral antidiabetic agents or insulin, glycaemic control should be closely monitored during the first month of treatment with an ACE inhibitor (see section 4.5).</p><p><strong>Linked to amlodipine:</strong></p><p><u>Precautions for use</u></p><p>The safety and efficacy of amlodipine in hypertensive crisis has not been established.</p><p><em>Cardiac failure:</em></p><p>Patients with heart failure should be treated with caution.</p><p>In a long-term, placebo controlled study in patients with severe heart failure (NYHA class III and IV) the reported incidence of pulmonary oedema was higher in the amlodipine treated group than in the placebo group (see section 5.1). Calcium channel blockers, including amlodipine, should be used with caution in patients with congestive heart failure, as they may increase the risk of future cardiovascular events and mortality.</p><p><em>Hepatic impairement:</em></p><p>The half-life of amlodipine is prolonged and AUC values are higher in patients with impaired liver function; dosage recommendations have not been established. Amlodipine should therefore be initiated at the lower end of the dosing range and caution should be used, both on initial treatment and when increasing the dose. Slow dose titration and careful monitoring may be required in patients with severe hepatic impairment.</p><p><em>Elderly:</em></p><p>In the elderly increase of the dosage should take place with care (see sections 4.2 and 5.2).</p><p><em>Renal failure:</em></p><p>Amlodipine may be used in such patients at normal doses. Changes in amlodipine plasma concentrations are not correlated with degree of renal impairment. Amlodipine is not dialysable.</p><p><strong>Linked to Pratima Duo</strong></p><p>All warnings related to each monocomponent, as listed above, should apply also to the fixed combination of Pratima Duo.</p><p><u>Precautions for use</u></p><p><em>Interactions;</em></p><p>The concomitant use of Pratima Duo with lithium, potassium-sparing drugs or potassium supplements, or dantrolene is not recommended (see section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Linked to perindopril </strong></p><p>Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</p><p><u>Drugs increasing the risk of angioedema </u></p><p>Concomitant use of ACE inhibitors with sacubitril/valsartan is contraindicated as this increases the risk of angioedema (see section 4.3 and 4.4). Sacubitril/valsartan must not be started until 36 hours after taking the last dose of perindopril therapy. Perindopril therapy must not be started until 36 hours after the last dose of sacubitril/valsartan (see sections 4.3 and 4.4).</p><p>Concomitant use of ACE inhibitors with racecadotril, mTOR inhibitors (e.g. sirolimus, everolimus, temsirolimus) and gliptins (e.g. linagliptin, saxagliptin, sitagliptin, vildagliptin) may lead to an increased risk for angioedema (see section 4.4).</p><p><u>Drugs inducing hyperkalaemia: </u></p><p>Although serum potassium usually remains within normal limits, hyperkalaemia may occur in some patients treated with Pratima Duo. Some drugs or therapeutic classes may increase the occurrence of hyperkalaemia: aliskiren, potassium salts, potassium-sparing diuretics (e.g. spironolactone, triamterene or amiloride), ACE inhibitors, angiotensin-II receptors antagonists, NSAIDs, heparins, immunosuppressant agents such as ciclosporin or tacrolimus, trimethoprim and cotrimoxazole (trimethoprim/sulfamethoxazole), as trimethoprim is known to act as a potassium-sparing diuretic like amiloride. The combination of these drugs increases the risk of hyperkalaemia. Therefore, the combination of Pratima Duo with the above-mentioned drugs is not recommended. If concomitant use is indicated, they should be used with caution and with frequent monitoring of serum potassium.</p><p><u>Concomitant use contra-indicated (see section 4.3): </u></p><p><em>Aliskiren: </em></p><p>In diabetic or impaired renal patients, risk of hyperkalaemia, worsening of renal function and cardiovascular morbidity and mortality increase.</p><p><em>Extracorporeal treatments: </em></p><p>Extracorporeal treatments leading to contact of blood with negatively charged surfaces such as dialysis or haemofiltration with certain high-flux membranes (e.g. polyacrylonitril membranes) and low density lipoprotein apheresis with dextran sulphate due to increased risk of severe anaphylactoid reactions (see section 4.3). If such treatment is required, consideration should be given to using a different type of dialysis membrane or a different class of antihypertensive agent.</p><p><u>Concomitant use not recommended (see section 4.4): </u></p><p><em>Aliskiren: </em></p><p>In patients other than diabetic or impaired renal patients, risk of hyperkalaemia, worsening of renal function and cardiovascular morbidity and mortality increase.</p><p><em>Concomitant therapy with ACE inhibitor and angiotensin-receptor blocker: </em></p><p>It has been reported in the literature that in patients with established atherosclerotic disease, heart failure, or with diabetes with end organ damage, concomitant therapy with ACE inhibitor and angiotensin-receptor blocker is associated with a higher frequency of hypotension, syncope, hyperkalaemia, and worsening renal function (including acute renal failure) as compared to use of a single renin-angiotensin-aldosterone system agent. Dual blockade (e.g, by combining an ACE-inhibitor with an angiotensin II receptor antagonist) should be limited to individually defined cases with close monitoring of renal function, potassium levels, and blood pressure.</p><p><em>Estramustine: </em></p><p>Risk of increased adverse effects such as angioneurotic oedema (angioedema).</p><p><em>Potassium-sparing diuretics (e.g. triamterene, amiloride...), potassium salts: </em></p><p>Hyperkalaemia (potentially lethal), especially in conjunction with renal impairment (additive hyperkalaemic effects).</p><p>The combination of perindopril with the above-mentioned drugs is not recommended (see section 4.4). If concomitant use is nonetheless indicated, they should be used with caution and with frequent monitoring of serum potassium. For use of spironolactone in heart failure, see below.</p><p><em>Lithium: </em></p><p>Reversible increases in serum lithium concentrations and toxicity (severe neurotoxicity) have been reported during concurrent use of ACE inhibitors. The combination of perindopril with lithium is not recommended. If the combination proves necessary, careful monitoring of serum lithium levels is recommended (see section 4.4).</p><p><u>Concomitant use which requires special care: </u></p><p><em>Antidiabetic agents (insulins, oral hypoglycaemic agents): </em></p><p>Epidemiological studies have suggested that concomitant administration of ACE inhibitors and antidiabetic medicines (insulins, oral hypoglycaemic agents) may cause an increased blood-glucose lowering effect with risk of hypoglycaemia. This phenomenon appeared to be more likely to occur during the first weeks of combined treatment and in patients with renal impairment.</p><p><em>Non-potassium-sparing diuretics: </em></p><p>Patients on diuretics, and especially those who are volume and/or salt depleted, may experience excessive reduction in blood pressure after initiation of therapy with an ACE inhibitor. The possibility of hypotensive effects can be reduced by discontinuation of the diuretic, by increasing volume or salt intake prior to initiating therapy with low and progressive doses of perindopril.</p><p>In arterial hypertension, when prior diuretic therapy can have caused salt/volume depletion, either the diuretic must be discontinued before initiating the ACE inhibitor, in which case a non-potassium-sparing diuretic can be thereafter reintroduced or the ACE inhibitor must be initiated with a low dosage and progressively increased. &nbsp;</p><p>In diuretic-treated congestive heart failure,<em> </em>the ACE inhibitor should be initiated at a very low dosage, possibly after reducing the dosage of the associated non-potassium-sparing diuretic.</p><p>In all cases, renal function (creatinine levels) must be monitored during the first few weeks of ACE inhibitor therapy.</p><p><em>Potassium-sparing diuretics (eplerenone, spironolactone): </em></p><p>With eplerenone or spironolactone at doses between 12.5 mg to 50 mg by day and with low doses of ACE inhibitors:</p><p>In the treatment of class II-IV heart failure (NYHA) with an ejection fraction &lt;40%, and previously treated with ACE inhibitors and loop diuretics, risk of hyperkalaemia, potentially lethal, especially in case of non-observance of the prescription recommendations on this combination.</p><p>Before initiating the combination, check the absence of hyperkalaemia and renal impairment.</p><p>A close monitoring of the kalaemia and creatininemia is recommended in the first month of the treatment once a week at the beginning and, monthly thereafter.</p><p><em>Non-steroidal anti-inflammatory medicinal products (NSAIDs) including acetylsalicylic acid </em>&ge; <em>3 g/day: </em></p><p>When ACE-inhibitors are administered simultaneously with non-steroidal anti-inflammatory drugs (i.e. acetylsalicylic acid at anti-inflammatory dosage regimens, COX-2 inhibitors and non-selective NSAIDs), attenuation of the antihypertensive effect may occur. Concomitant use of ACE-inhibitors and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function. The combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter.</p><p><u>Concomitant use which requires some care: </u></p><p><em>Sympathomimetics: </em></p><p>Sympathomimetics may reduce the antihypertensive effects of ACE inhibitors.</p><p><em>Gold: </em></p><p>Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including perindopril. &nbsp;</p><p><strong>Linked to amlodipine </strong></p><p><u>Concomitant use not recommended: </u></p><p>Dantrolene (infusion): In animals, lethal ventricular fibrillation and cardiovascular collapse are observed in association with hyperkalemia after administration of verapamil and intravenous dantrolene. Due to risk of hyperkalemia, it is recommended that the co-administration of calcium channel blockers such as amlodipine be avoided in patients susceptible to malignant hyperthermia and in the management of malignant hyperthermia. &nbsp;</p><p><u>Concomitant use which requires special care: </u></p><p>CYP3A4 inducers: Upon co-administration of known inducers of the CYP3A4, the plasma concentration of amlodipine may vary. Therefore, blood pressure should be monitored and dose regulation considered both during and after concomitant medication particularly with strong CYP3A4 inducers (e.g. rifampicin, hypericum perforatum). &nbsp;</p><p>CYP3A4 inhibitors: Concomitant use of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors, azole antifungals, macrolides like erythromycin or clarithromycin, verapamil or diltiazem) may give rise to significant increase in amlodipine exposure. The clinical translation of these PK variations may be more pronounced in the elderly. Clinical monitoring and dose adjustment may thus be required. &nbsp;</p><p>There is an increased risk of hypotension in patients receiving clarithromycin with amlodipine. Close observation of patients is recommended when amlodipine is co administered with clarithromycin. &nbsp;</p><p><u>Concomitant use to be taken into consideration: </u></p><p>The blood pressure lowering effects of amlodipine adds to the blood pressure-lowering effects of other medicinal products with antihypertensive properties. &nbsp;</p><p><u>Tacrolimus: </u></p><p>There is a risk of increased tacrolimus blood levels when co administered with amlodipine. In order to avoid toxicity of tacrolimus, administration of amlodipine in a patient treated with tacrolimus requires monitoring of tacrolimus blood levels and dose adjustment of tacrolimus when appropriate. &nbsp;</p><p><em>Mechanistic Target of Rapamycin (mTOR) Inhibitors </em></p><p>mTOR inhibitors such as sirolimus, temsirolimus, and everolimus are CYP3A substrates. Amlodipine is a weak CYP3A inhibitor. With concomitant use of mTOR inhibitors, amlodipine may increase exposure of mTOR inhibitors. &nbsp;</p><p><u>Ciclosporine: </u></p><p>No drug interaction studies have been conducted with ciclosporine and amlodipine in healthy volunteers or other populations with the exception of renal transplant patients, where variable trough concentration increases (average 0% - 40%) of ciclosporine were observed. Consideration should be given for monitoring ciclosporine levels in renal transplant patients on amlodipine, and ciclosporine dose reductions should be made as necessary. &nbsp;</p><p><u>Simvastatin: </u></p><p>Co-administration of multiple doses of 10 mg of amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. Limit the dose of simvastatin in patients on amlodipine to 20 mg daily. &nbsp;</p><p><u>Others combinations: </u></p><p>In clinical interaction studies, amlodipine did not affect the pharmacokinetics of atorvastatin, digoxin, warfarin. &nbsp;</p><p>Administration of amlodipine with grapefruit or grapefruit juice is not recommended as bioavailability may be increased in some patients resulting in increased blood pressure lowering effects. &nbsp;</p><p><strong>Linked to Pratima Duo: </strong></p><p><u>Concomitant use which requires special care: </u></p><p><em>Baclofen: </em></p><p>Increased antihypertensive effect. Monitor blood pressure and adapt antihypertensive dosage if necessary.</p><p><u>Concomitant use to be taken into consideration: </u></p><ul><li>Antihypertensive agents (such as beta-blockers) and vasodilatators: &nbsp;&nbsp;</li><li>Concomitant use of these agents may increase the hypotensive effects of perindopril and amlodipine. Concomitant use with nitroglycerine and other nitrates or other vasodilatators, may further reduce blood pressure and therefore should be considered with caution.</li><li>Corticosteroids, tetracosactide: reduction in antihypertensive effect (salt and water retention due to corticosteroids).</li><li>Alpha-blockers (prazosin, alfuzosin, doxazosin, tamsulosin, terazosin): increased antihypertensive effect and increased risk of orthostatic hypotension.</li><li>Amifostine: may potentiate the antihypertensive effect of amlodipine. &nbsp;</li><li>Tricyclic antidepressants/antipsychotics/anaesthetics: increased antihypertensive effect and increased risk of orthostatic hypotension.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Given the effects of the individual components in this combination product on pregnancy and lactation:</p><p>Pratima Duo is not recommended during the first trimester of pregnancy. Pratima Duo is contraindicated during the second and third trimesters of pregnancy.</p><p>Pratima Duo is not recommended during lactation. A decision should therefore be made whether to discontinue nursing or to discontinue Pratima Duo taking account the importance of this therapy for the mother.</p><p><strong>Pregnancy: </strong></p><p><u>Linked to perindopril </u></p><p>The use of ACE inhibitors is not recommended during the first trimester of pregnancy (see section 4.4). The use of ACE inhibitors is contraindicated during the second and third trimester of pregnancy (see sections 4.3 and 4.4).</p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Unless continued ACE inhibitor therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should be started.</p><p>Exposure to ACE inhibitor therapy during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see section 5.3).</p><p>Should exposure to ACE inhibitor have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.</p><p>Infants whose mothers have taken ACE inhibitors should be closely observed for hypotension (see sections 4.3 and 4.4).</p><p><u>Linked to amlodipine </u></p><p>The safety of amlodipine in human pregnancy has not been established.</p><p>In animal studies, reproductive toxicity was observed at high doses (see section 5.3). Use in pregnancy is only recommended when there is no safer alternative and when the disease itself carries greater risk for the mother and foetus.</p><p><strong>Breast-feeding: </strong></p><p><u>Linked to perindopril </u></p><p>Because no information is available regarding the use of perindopril during breastfeeding, perindopril is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</p><p><u>Linked to amlodipine </u></p><p>Amlodipine is excreted in human milk. The proportion of the maternal dose received by the infant has been estimated with an interquartile range of 3 &ndash; 7%, with a maximum of 15%. The effect of amlodipine on infants is unknown. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with amlodipine should be made taking into account the benefit of breast-feeding to the child and the benefit of amlodipine therapy to the mother.</p><p><strong>Fertility: </strong></p><p><u>Linked to perindopril </u></p><p>There was no effect on reproductive performance or fertility.</p><p><u>Linked to amlodipine </u></p><p>Reversible biochemical changes in the head of spermatozoa have been reported in some patients treated by calcium channel blockers. Clinical data are insufficient regarding the potential effect of amlodipine on fertility. In one rat study, adverse effects were found on male fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects of perindopril and amlodipine on the ability to drive and use machines have been performed. Amlodipine can have minor or moderate influence on the ability to drive and use machines. If patients suffer from dizziness, headache, fatigue, weariness or nausea, the ability to react may be impaired. Caution is recommended especially at the start of treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Summary of safety profile </strong></p><p>The most commonly reported adverse reactions with perindopril and amlodipine given separately are: oedema, somnolence, dizziness, headache (especially at the beginning of the treatment), dysgeusia, paraesthesia, visual impairment (including diplopia), tinnitus, vertigo, palpitations, flushing, hypotension (and effects related to hypotension), dyspnoea, cough, abdominal pain, nausea, vomiting, dyspepsia, change of bowel habit, diarrheoa, constipation, prurit, rash, exanthema, joint swelling (ankle swelling), muscle spasms, fatigue, asthenia.</p><p><strong>Tabulated list of adverse reactions: </strong></p><p>The following undesirable effects have been observed during clinical trials and/or post-marketing use with perindopril or amlodipine given separately and ranked under the MedDRA classification by body system and under the following frequency:</p><p>Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1000 to &lt;1/100); rare (&ge;1/10000 to &lt;1/1000); very rare (&lt;1/10000); not known (cannot be estimated from the available data).<strong> &nbsp;&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:1215px"><tbody><tr><td rowspan="2" style="width:312px"><p><strong>MedDRA System Organ Class</strong></p></td><td rowspan="2" style="width:666px"><p><strong>Undesirable effects</strong></p></td><td colspan="2" style="width:236px"><p><strong>Frequency</strong></p></td></tr><tr><td style="width:77px"><p><strong>Amlodipine </strong></p></td><td style="width:159px"><p><strong>Perindopril </strong></p></td></tr><tr><td style="width:312px"><p><strong>Infections and infestations</strong></p></td><td style="width:666px"><p>Rhinitis</p></td><td style="width:77px"><p>Uncommon</p></td><td style="width:159px"><p>Very rare</p></td></tr><tr><td rowspan="5" style="width:312px"><p><strong>Blood and the lymphatic System Disorders </strong></p></td><td style="width:666px"><p>Eosinophilia</p></td><td style="width:77px"><p>-</p></td><td style="width:159px"><p>Uncommon*</p></td></tr><tr><td style="width:666px"><p>Leukopenia/neutropenia (see section 4.4)</p></td><td style="width:77px"><p>Very rare</p></td><td style="width:159px"><p>Very rare</p></td></tr><tr><td style="width:666px"><p>Agranulocytosis or pancytopenia (see section 4.4)</p></td><td style="width:77px"><p>-</p></td><td style="width:159px"><p>Very rare</p></td></tr><tr><td style="width:666px"><p>Thrombocytopenia (see section 4.4)</p></td><td style="width:77px"><p>Very rare</p></td><td style="width:159px"><p>Very rare</p></td></tr><tr><td style="width:666px"><p>Haemolytic anaemia enzyme specific in patients with a congenital deficiency of G-6PDH (see section 4.4)</p></td><td style="width:77px"><p>-</p></td><td style="width:159px"><p>Very rare</p></td></tr><tr><td style="width:312px"><p><strong>Immune System Disorders </strong></p></td><td style="width:666px"><p>Hypersensitivity</p></td><td style="width:77px"><p>Very rare</p></td><td style="width:159px"><p>Uncommon</p></td></tr><tr><td rowspan="4" style="width:312px"><p><strong>Metabolism and Nutrition Disorders </strong></p><p>&nbsp;</p></td><td style="width:666px"><p>Hypoglycaemia (see sections 4.4 and 4.5)</p></td><td style="width:77px"><p>-</p></td><td style="width:159px"><p>Uncommon*</p></td></tr><tr><td style="width:666px"><p>Hyperkalaemia, reversible on discontinuation (see section 4.4)</p></td><td style="width:77px"><p>-</p></td><td style="width:159px"><p>Uncommon*</p></td></tr><tr><td style="width:666px"><p>Hyponatraemia</p></td><td style="width:77px"><p>-</p></td><td style="width:159px"><p>Uncommon*</p></td></tr><tr><td style="width:666px"><p>Hyperglycaemia</p></td><td style="width:77px"><p>Very rare</p></td><td style="width:159px"><p>-</p></td></tr><tr><td rowspan="4" style="width:312px"><p><strong>Psychiatric disorders</strong></p></td><td style="width:666px"><p>Insomnia</p></td><td style="width:77px"><p>Uncommon</p></td><td style="width:159px"><p>-</p></td></tr><tr><td style="width:666px"><p>Mood altered (including anxiety)</p></td><td style="width:77px"><p>Uncommon</p></td><td style="width:159px"><p>Uncommon</p></td></tr><tr><td style="width:666px"><p>Depression</p></td><td style="width:77px"><p>Uncommon</p></td><td style="width:159px"><p>-</p></td></tr><tr><td style="width:666px"><p>Sleep disorder</p></td><td style="width:77px"><p>-</p></td><td style="width:159px"><p>Uncommon</p></td></tr><tr><td rowspan="13" style="width:312px"><p><strong>Nervous System disorders </strong></p></td><td style="width:666px"><p>Somnolence (especially at the beginning of the treatment)</p></td><td style="width:77px"><p>Common</p></td><td style="width:159px"><p>-</p></td></tr><tr><td style="width:666px"><p>Dizziness (especially at the beginning of the treatment)</p></td><td style="width:77px"><p>Common</p></td><td style="width:159px"><p>Common</p></td></tr><tr><td style="width:666px"><p>Headache (especially at the beginning of the treatment)</p></td><td style="width:77px"><p>Common</p></td><td style="width:159px"><p>Common</p></td></tr><tr><td style="width:666px"><p>Dysgeusia</p></td><td style="width:77px"><p>Uncommon</p></td><td style="width:159px"><p>Common</p></td></tr><tr><td style="width:666px"><p>Tremor</p></td><td style="width:77px"><p>Uncommon</p></td><td style="width:159px"><p>-</p></td></tr><tr><td style="width:666px"><p>Hypoaesthesia</p></td><td style="width:77px"><p>Uncommon</p></td><td style="width:159px"><p>-</p></td></tr><tr><td style="width:666px"><p>Paraesthesia</p></td><td style="width:77px"><p>Uncommon</p></td><td style="width:159px"><p>Common</p></td></tr><tr><td style="width:666px"><p>Syncope</p></td><td style="width:77px"><p>Uncommon</p></td><td style="width:159px"><p>Uncommon</p></td></tr><tr><td style="width:666px"><p>Confusional state</p></td><td style="width:77px"><p>Rare</p></td><td style="width:159px"><p>Very rare</p></td></tr><tr><td style="width:666px"><p>Hypertonia</p></td><td style="width:77px"><p>Very rare</p></td><td style="width:159px"><p>-</p></td></tr><tr><td style="width:666px"><p>Neuropathy peripheral</p></td><td style="width:77px"><p>Very rare</p></td><td style="width:159px"><p>-</p></td></tr><tr><td style="width:666px"><p>Cerebrovascular accident possibly secondary to excessive hypotension in high-risk patients (see section 4.4)</p></td><td style="width:77px"><p>-</p></td><td style="width:159px"><p>Very rare</p></td></tr><tr><td style="width:666px"><p>Extrapyramidal disorder (extrapyramidal syndrome)</p></td><td style="width:77px"><p>Not known</p></td><td style="width:159px"><p>-</p></td></tr><tr><td rowspan="2" style="width:312px"><p><strong>Eye Disorders </strong></p></td><td style="width:666px"><p>Visual impairment</p></td><td style="width:77px"><p>Common</p></td><td style="width:159px"><p>Common</p></td></tr><tr><td style="width:666px"><p>Diplopia</p></td><td style="width:77px"><p>Common</p></td><td style="width:159px"><p>-</p></td></tr><tr><td rowspan="2" style="width:312px"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="width:666px"><p>Tinnitus</p></td><td style="width:77px"><p>Uncommon</p></td><td style="width:159px"><p>Common</p></td></tr><tr><td style="width:666px"><p>Vertigo</p></td><td style="width:77px"><p>-</p></td><td style="width:159px"><p>Common</p></td></tr><tr><td rowspan="5" style="width:312px"><p><strong>Cardiac Disorders</strong></p></td><td style="width:666px"><p>Palpitations</p></td><td style="width:77px"><p>Common</p></td><td style="width:159px"><p>Uncommon *</p></td></tr><tr><td style="width:666px"><p>Tachycardia</p></td><td style="width:77px"><p>-</p></td><td style="width:159px"><p>Uncommon *</p></td></tr><tr><td style="width:666px"><p>Angina pectoris (see section 4.4)</p></td><td style="width:77px"><p>-</p></td><td style="width:159px"><p>Very rare</p></td></tr><tr><td style="width:666px"><p>Myocardial infarction, possibly secondary to excessive hypotension in high risk patients (see section 4.4)</p></td><td style="width:77px"><p>Very rare</p></td><td style="width:159px"><p>Very rare</p></td></tr><tr><td style="width:666px"><p>Arrythmia (including bradycardia, ventricular tachycardia and atrial fibrillation)</p></td><td style="width:77px"><p>Uncommon</p></td><td style="width:159px"><p>Very rare</p></td></tr><tr><td rowspan="4" style="width:312px"><p><strong>Vascular Disorders</strong></p></td><td style="width:666px"><p>Flushing</p></td><td style="width:77px"><p>Common</p></td><td style="width:159px"><p>-</p></td></tr><tr><td style="width:666px"><p>Hypotension (and effects related to hypotension)</p></td><td style="width:77px"><p>Uncommon</p></td><td style="width:159px"><p>Common</p></td></tr><tr><td style="width:666px"><p>Vasculitis</p></td><td style="width:77px"><p>Very Rare</p></td><td style="width:159px"><p>Uncommon *</p></td></tr><tr><td style="width:666px"><p>Raynaud&rsquo;s phenomenon</p></td><td style="width:77px"><p>-</p></td><td style="width:159px"><p>Not known</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="4"><p><strong>Respiratory, Thoracic and Mediastinal Disorders</strong></p></td><td style="width:657px"><p>Dyspnoea</p></td><td style="width:90px"><p>Common</p></td><td style="width:152px"><p>Common</p></td></tr><tr><td style="width:657px"><p>Cough</p></td><td style="width:90px"><p>Uncommon</p></td><td style="width:152px"><p>Common</p></td></tr><tr><td style="width:657px"><p>Bronchospasm</p></td><td style="width:90px"><p>-</p></td><td style="width:152px"><p>Uncommon</p></td></tr><tr><td style="width:657px"><p>Eosinophilic pneumonia</p></td><td style="width:90px"><p>-</p></td><td style="width:152px"><p>Very rare</p></td></tr><tr><td rowspan="11"><p><strong>Gastro-intestinal Disorders</strong></p></td><td style="width:657px"><p>Gingival hyperplasia</p></td><td style="width:90px"><p>Very rare</p></td><td style="width:152px"><p>-</p></td></tr><tr><td style="width:657px"><p>Abdominal pain</p></td><td style="width:90px"><p>Common</p></td><td style="width:152px"><p>Common</p></td></tr><tr><td style="width:657px"><p>Nausea</p></td><td style="width:90px"><p>Common</p></td><td style="width:152px"><p>Common</p></td></tr><tr><td style="width:657px"><p>Vomiting</p></td><td style="width:90px"><p>Uncommon</p></td><td style="width:152px"><p>Common</p></td></tr><tr><td style="width:657px"><p>Dyspepsia</p></td><td style="width:90px"><p>Common</p></td><td style="width:152px"><p>Common</p></td></tr><tr><td style="width:657px"><p>Change of bowel habit</p></td><td style="width:90px"><p>Common</p></td><td style="width:152px"><p>-</p></td></tr><tr><td style="width:657px"><p>Dry mouth</p></td><td style="width:90px"><p>Uncommon</p></td><td style="width:152px"><p>Uncommon</p></td></tr><tr><td style="width:657px"><p>Diarrheoa</p></td><td style="width:90px"><p>Common</p></td><td style="width:152px"><p>Common</p></td></tr><tr><td style="width:657px"><p>Constipation</p></td><td style="width:90px"><p>Common</p></td><td style="width:152px"><p>Common</p></td></tr><tr><td style="width:657px"><p>Pancreatitis</p></td><td style="width:90px"><p>Very rare</p></td><td style="width:152px"><p>Very rare</p></td></tr><tr><td style="width:657px"><p>Gastritis</p></td><td style="width:90px"><p>Very rare</p></td><td style="width:152px"><p>-</p></td></tr><tr><td rowspan="2"><p><strong>Hepato-biliary Disorders</strong></p></td><td style="width:657px"><p>Hepatitis, jaundice</p><p>Hepatitis either cytolitic or cholestatic (see section 4.4)</p></td><td style="width:90px"><p>Very rare</p><p>-</p></td><td style="width:152px"><p>-</p><p>Very rare</p></td></tr><tr><td style="width:657px"><p>Hepatic enzymes increased (mostly consistent with cholestasis)</p></td><td style="width:90px"><p>Very rare</p></td><td style="width:152px"><p>-</p></td></tr><tr><td rowspan="15"><p><strong>Skin and Subcutaneous Tissue Disorders</strong></p></td><td style="width:657px"><p>Quincke&rsquo;s oedema Angioedema of face, extremities, lips, mucous membranes, tongue, glottis and/or larynx (see section 4.4)</p></td><td style="width:90px"><p>Very rare</p><p>Very rare</p></td><td style="width:152px"><p>-</p><p>Uncommon</p></td></tr><tr><td style="width:657px"><p>Erythema multiform</p></td><td style="width:90px"><p>Very rare</p></td><td style="width:152px"><p>Very rare</p></td></tr><tr><td style="width:657px"><p>Alopecia</p></td><td style="width:90px"><p>Uncommon</p></td><td style="width:152px"><p>-</p></td></tr><tr><td style="width:657px"><p>Purpura</p></td><td style="width:90px"><p>Uncommon</p></td><td style="width:152px"><p>-</p></td></tr><tr><td style="width:657px"><p>Skin discolouration</p></td><td style="width:90px"><p>Uncommon</p></td><td style="width:152px"><p>Uncommon</p></td></tr><tr><td style="width:657px"><p>Hyperhidrosis</p></td><td style="width:90px"><p>Uncommon</p></td><td style="width:152px"><p>&nbsp;</p></td></tr><tr><td style="width:657px"><p>Prurit</p></td><td style="width:90px"><p>Uncommon</p></td><td style="width:152px"><p>Common</p></td></tr><tr><td style="width:657px"><p>Rash, exanthema</p></td><td style="width:90px"><p>Uncommon</p></td><td style="width:152px"><p>Common</p></td></tr><tr><td style="width:657px"><p>Urticaria (see section 4.4)</p></td><td style="width:90px"><p>Uncommon</p></td><td style="width:152px"><p>Uncommon</p></td></tr><tr><td style="width:657px"><p>Photosentivity reactions</p></td><td style="width:90px"><p>Very rare</p></td><td style="width:152px"><p>Uncommon *</p></td></tr><tr><td style="width:657px"><p>Pemphigoid</p></td><td style="width:90px"><p>-</p></td><td style="width:152px"><p>Uncommon *</p></td></tr><tr><td style="width:657px"><p>Psoriasis aggravation</p></td><td style="width:90px"><p>-</p></td><td style="width:152px"><p>Rare</p></td></tr><tr><td style="width:657px"><p>Stevens-Johnson Syndrome</p></td><td style="width:90px"><p>Very rare</p></td><td style="width:152px"><p>-</p></td></tr><tr><td style="width:657px"><p>Exfoliative dermatitis</p></td><td style="width:90px"><p>Very rare</p></td><td style="width:152px"><p>-</p></td></tr><tr><td style="width:657px"><p>Toxic epidermal necrolysis</p></td><td style="width:90px"><p>Not known</p></td><td style="width:152px"><p>&nbsp;</p></td></tr><tr><td rowspan="5"><p><strong>Musculoskeletal and Connective Tissue Disorders</strong></p></td><td style="width:657px"><p>Joint swelling (ankle swelling)</p></td><td style="width:90px"><p>Common</p></td><td style="width:152px"><p>-</p></td></tr><tr><td style="width:657px"><p>Arthralgia</p></td><td style="width:90px"><p>Uncommon</p></td><td style="width:152px"><p>Uncommon *</p></td></tr><tr><td style="width:657px"><p>Myalgia</p></td><td style="width:90px"><p>Uncommon</p></td><td style="width:152px"><p>Uncommon *</p></td></tr><tr><td style="width:657px"><p>Muscle spasms</p></td><td style="width:90px"><p>Common</p></td><td style="width:152px"><p>Common</p></td></tr><tr><td style="width:657px"><p>Back pain</p></td><td style="width:90px"><p>Uncommon</p></td><td style="width:152px"><p>-</p></td></tr><tr><td rowspan="3"><p><strong>Renal and Urinary Disorders</strong></p></td><td style="width:657px"><p>Micturition disorder, nocturia, pollakiuria</p></td><td style="width:90px"><p>Uncommon</p></td><td style="width:152px"><p>-</p></td></tr><tr><td style="width:657px"><p>Renal failure</p></td><td style="width:90px"><p>-</p></td><td style="width:152px"><p>Uncommon</p></td></tr><tr><td style="width:657px"><p>Renal failure acute</p></td><td style="width:90px"><p>-</p></td><td style="width:152px"><p>Very rare</p></td></tr><tr><td rowspan="2"><p><strong>Reproductive System and Breast Disorders</strong></p></td><td style="width:657px"><p>Erectile dysfunction</p></td><td style="width:90px"><p>Uncommon</p></td><td style="width:152px"><p>Uncommon</p></td></tr><tr><td style="width:657px"><p>Gynaecomastia</p></td><td style="width:90px"><p>Uncommon</p></td><td style="width:152px"><p>-</p></td></tr><tr><td rowspan="8"><p><strong>General Disorders and Administration Site Condition</strong></p></td><td style="width:657px"><p>Oedema</p></td><td style="width:90px"><p>Very common</p></td><td style="width:152px"><p>-</p></td></tr><tr><td style="width:657px"><p>Oedema peripheral</p></td><td style="width:90px"><p>-</p></td><td style="width:152px"><p>Uncommon *</p></td></tr><tr><td style="width:657px"><p>Fatigue</p></td><td style="width:90px"><p>Common</p></td><td style="width:152px"><p>-</p></td></tr><tr><td style="width:657px"><p>Chest pain</p></td><td style="width:90px"><p>Uncommon</p></td><td style="width:152px"><p>Uncommon *</p></td></tr><tr><td style="width:657px"><p>Asthenia</p></td><td style="width:90px"><p>Common</p></td><td style="width:152px"><p>Common</p></td></tr><tr><td style="width:657px"><p>Pain</p></td><td style="width:90px"><p>Uncommon</p></td><td style="width:152px"><p>-</p></td></tr><tr><td style="width:657px"><p>Malaise</p></td><td style="width:90px"><p>Uncommon</p></td><td style="width:152px"><p>Uncommon *</p></td></tr><tr><td style="width:657px"><p>Pyrexia</p></td><td style="width:90px"><p>-</p></td><td style="width:152px"><p>Uncommon *</p></td></tr><tr><td rowspan="6"><p><strong>Investigations</strong></p></td><td style="width:657px"><p>Weight increased, weight decreased</p></td><td style="width:90px"><p>Uncommon</p></td><td style="width:152px"><p>-</p></td></tr><tr><td style="width:657px"><p>Blood urea increased</p></td><td style="width:90px"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -</p></td><td style="width:152px"><p>Uncommon *</p></td></tr><tr><td style="width:657px"><p>Blood creatinine increased</p></td><td style="width:90px"><p>-</p></td><td style="width:152px"><p>Uncommon *</p></td></tr><tr><td style="width:657px"><p>Blood bilirubin increase</p></td><td style="width:90px"><p>-</p></td><td style="width:152px"><p>Rare</p></td></tr><tr><td style="width:657px"><p>Hepatic enzyme increase</p></td><td style="width:90px"><p>-</p></td><td style="width:152px"><p>Rare</p></td></tr><tr><td style="width:657px"><p>Haemoglobin decreased and haematocrit decreased</p></td><td style="width:90px"><p>-</p></td><td style="width:152px"><p>Very rare</p></td></tr><tr><td><p><strong>Injury, poisoning and procedural complications</strong></p></td><td style="width:657px"><p>Fall</p><p>&nbsp;</p></td><td style="width:90px"><p>-</p></td><td style="width:152px"><p>Uncommon *</p></td></tr></tbody></table><p><em>* Frequency calculated from clinical trials for adverse events detected from spontaneous report </em></p><p>Cases of SIADH have been reported with other ACE inhibitors. SIADH can be considered as a very rare but possible complication associated with ACE inhibitor therapy including perindopril.</p><p><strong>Reporting of suspected adverse reactions </strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&bull;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States</p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no information on overdosage with perindopril and amlodipine in humans. &nbsp;</p><p>For amlodipine, experience with intentional overdose in humans is limited. Symptoms: available data suggest that gross overdosage could result in excessive peripheral vasodilatation and possibly reflex tachycardia. Marked and probably prolonged systemic hypotension up to and including shock with fatal outcome have been reported.</p><p>Treatment: clinically significant hypotension due to amlodipine overdosage calls for active cardiovascular support including frequent monitoring of cardiac and respiratory function, elevation of extremities and attention to circulating fluid volume and urine output.</p><p>A vasoconstrictor may be helpful in restoring vascular tone and blood pressure, provided that there is no contraindication to its use. Intravenous calcium gluconate may be beneficial in reversing the effects of calcium channel blockade.</p><p>Gastric lavage may be worthwhile in some cases. In healthy volunteers the use of charcoal up to 2 hours after administration of amlodipine 10 mg has been shown to reduce the absorption rate of amlodipine. Since amlodipine is highly protein-bound, dialysis is not likely to be of benefit.</p><p>For perindopril, limited data are available for overdosage in humans. Symptoms associated with the overdosage of ACE inhibitors may include hypotension, circulatory shock, electrolyte disturbances, renal failure, hyperventilation, tachycardia, palpitations, bradycardia, dizziness, anxiety, and cough.</p><p>The recommended treatment of overdosage is intravenous infusion of normal saline solution. If hypotension occurs, the patient should be placed in the shock position. If available, treatment with angiotensin II infusion and/or intravenous catecholamines may also be considered. Periondopril can be removed from the systemic circulation by haemodialysis (see section 4.4). Pacemaker therapy is indicated for treatment-resistant bradycardia. Vital signs, serum electrolytes and creatinine concentrations should be monitored continuously.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: ACE inhibitors and calcium channel blockers, ATC code: C09BB04.</p><p><strong>Perindopril:</strong></p><p><u>Mechanism of action:</u></p><p>Perindopril is an inhibitor of the enzyme that converts angiotensin I into angiotensin II (Angiotensin Converting Enzyme ACE). The converting enzyme, or kinase, is an exopeptidase that allows conversion of angiotensin I into the vasoconstrictor angiotensin II as well as causing the degradation of the vasodilator bradykinin into an inactive heptapeptide. Inhibition of ACE results in a reduction of angiotensin II in the plasma, which leads to increased plasma renin activity (by inhibition of the negative feedback of renin release) and reduced secretion of aldosterone. Since ACE inactivates bradykinin, inhibition of ACE also results in an increased activity of circulating and local kallikrein-kinin systems (and thus also activation of the prostaglandin system). It is possible that this mechanism contributes to the blood pressure-lowering action of ACE inhibitors and is partially responsible for certain of their side effects (e.g. cough).</p><p>Perindopril acts through its active metabolite, perindoprilat. The other metabolites show no inhibition of ACE activity <em>in vitro.</em></p><p><u>Clinical efficacy and safety</u></p><p><em>Hypertension:</em></p><p>Perindopril is active in all grades of hypertension: mild, moderate, severe; a reduction in systolic and diastolic blood pressures in both supine and standing positions is observed.</p><p>Perindopril reduces peripheral vascular resistance, leading to blood pressure reduction. As a consequence, peripheral blood flow increases, with no effect on heart rate.</p><p>Renal blood flow increases as a rule, while the glomerular filtration rate (GFR) is usually unchanged.</p><p>The antihypertensive activity is maximal between 4 and 6 hours after a single dose and is sustained for at least 24 hours: trough effects are about 87-100% of peak effects.</p><p>The decrease in blood pressure occurs rapidly. In responding patients, normalisation is achieved within a month and persists without the occurrence of tachyphylaxis. Discontinuation of treatment does not lead to a rebound effect.</p><p>Perindopril reduces left ventricular hypertrophy.</p><p>In man, perindopril has been confirmed to demonstrate vasodilatory properties. It improves large artery elasticity and decreases the media:lumen ratio of small arteries.</p><p><em>Stable coronary artery disease: </em></p><p>The EUROPA study was a multicentre, international, randomised, double-blind, placebo-controlled clinical trial lasting 4 years.</p><p>Twelve thousand two hundred and eighteen (12218) patients aged over 18 were randomised to 8 mg perindopril tert-butylamine (equivalent to 10 mg perindopril arginine) (n=6110) or placebo (n=6108).</p><p>The trial population had evidence of coronary artery disease with no evidence of clinical signs of heart failure. Overall, 90% of the patients had a previous myocardial infarction and/or a previous coronary revascularisation. Most of the patients received the study medication on top of conventional therapy including platelet inhibitors, lipid lowering agents and beta-blockers. &nbsp;</p><p>The main efficacy criterion was the composite of cardiovascular mortality, non fatal myocardial infarction and/or cardiac arrest with successful resuscitation. The treatment with 8 mg perindopril tert-butylamine (equivalent to 10 mg perindopril arginine) once daily resulted in a significant absolute reduction in the primary endpoint of 1.9% (relative risk reduction of 20%, 95%CI [9.4; 28.6]&ndash; p&lt;0.001).</p><p>In patients with a history of myocardial infarction and/or revascularisation, an absolute reduction of 2.2% corresponding to a RRR of 22.4% (95%CI [12.0; 31.6] &ndash; &lt;0.001) in the primary endpoint was observed by comparison to placebo.</p><p><em>Dual blockade of the renin-angiotensin-aldosterone system (RAAS) clinical trial data:</em></p><p>Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of combination of an ACE-inhibitor with an angiotensin II receptor blocker.</p><p>ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.</p><p>These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed.</p><p>Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.</p><p>ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.</p><p>ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and 18 adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</p><p><strong>Amlodipine: </strong></p><p><u>Mechanism of action </u></p><p>Amlodipine is a calcium ion influx inhibitor of the dihydropyridine group (slow channel blocker or calcium ion antagonist) and inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle.</p><p>The mechanism of the antihypertensive action of amlodipine is due to a direct relaxant effect on vascular smooth muscle. The precise mechanism by which amlodipine relieves angina has not been fully determined but amlodipine reduces total ischaemic burden by the following two actions:</p><ul><li>Amlodipine dilates peripheral arterioles and thus, reduces the total peripheral resistance (afterload) against which the heart works. Since the heart rate remains stable, this unloading of the heart reduces myocardial energy consumption and oxygen requirements.</li><li>The mechanism of action of amlodipine also probably involves dilatation of the main coronary arteries and coronary arterioles, both in normal and ischaemic regions. This dilatation increases myocardial oxygen delivery in patients with coronary artery spasm (Prinzmetal&#39;s or variant angina).</li></ul><p><u>Clinical efficacy and safety </u></p><p>In patients with hypertension, once daily dosing provides clinically significant reductions of blood pressure in both the supine and standing positions throughout the 24 hour interval. Due to the slow onset of action, acute hypotension is not a feature of amlodipine administration.</p><p>In patients with angina, once daily administration of amlodipine increases total exercise time, time to angina onset, and time to 1mm ST segment depression, and decreases both angina attack frequency and glyceryl trinitrate tablet consumption.</p><p>Amlodipine has not been associated with any adverse metabolic effects or changes in plasma lipids and is suitable for use in patients with asthma, diabetes, and gout.</p><p><em>Coronary artery disease (CAD): </em></p><p>The effectiveness of amlodipine in preventing clinical events in patients with coronary artery disease (CAD) has been evaluated in an independent, multi-center, randomized, double- blind, placebo-controlled study of 1997 patients; Comparison of Amlodipine vs. Enalapril to Limit Occurrences of Thrombosis (CAMELOT). Of these patients, 663 were treated with amlodipine 5-10 mg, 673 patients were treated with enalapril 10-20 mg, and 655 patients were treated with placebo, in addition to standard care of statins, beta-blockers, diuretics and aspirin, for 2 years. The key efficacy results are presented in Table 1. The results indicate that amlodipine treatment was associated with fewer hospitalizations for angina and revascularization procedures in patients with CAD.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="6"><p><strong>Table 1. Incidence of significant clinical outcomes for CAMELOT</strong></p></td></tr><tr><td colspan="4"><p>Cardiovascular event rates, No. (%)</p></td><td colspan="2"><p>Amlodipine vs. placebo</p></td></tr><tr><td><p>Outcomes</p></td><td><p>Amlodipine</p></td><td><p>Placebo</p></td><td><p>Enalapril</p></td><td><p>Hazard Ratio (95% CI)</p></td><td><p>P Value</p></td></tr><tr><td><p><u>Primary Endpoint</u> Adverse cardiovascular events</p></td><td><p>110 (16.6)</p></td><td><p>151 (23.1)</p></td><td><p>136 (20.2)</p></td><td><p>0.69 (0.54-0.88)</p></td><td><p>003</p></td></tr><tr><td><p><u>Individual Components </u></p><p>Coronary revascularization</p><p>Hospitalization for angina</p><p>Nonfatal MI</p><p>Stroke or TIA</p><p>Cardiovascular death</p><p>Hospitalization for CHF</p><p>Resuscitated cardiac arrest</p><p>New-onset peripheral vascular disease</p></td><td><p>&nbsp;</p><p>78 (11.8)</p><p>51 (7.7)</p><p>14 (2.1)</p><p>6 (0.9)</p><p>5 (0.8)</p><p>3 (0.5)</p><p>0</p><p>5 (0.8)</p></td><td><p>&nbsp;</p><p>103 (15.7)</p><p>84 (12.8)</p><p>19 (2.9)</p><p>12 (1.8)</p><p>2 (0.3)</p><p>5 (0.8)</p><p>4 (0.6)</p><p>2 (0.3)</p></td><td><p>&nbsp;</p><p>95 (14.1)</p><p>86 (12.8)</p><p>11 (1.6)</p><p>8 (1.2)</p><p>5 (0.7)</p><p>4 (0.6)</p><p>1 (0.1)</p><p>8 (1.2)</p></td><td><p>&nbsp;</p><p>0.73 (0.54-0.98)</p><p>0.58 (0.41-0.82)</p><p>0.73 (0.37-1.46)</p><p>0.50 (0.19-1.32)</p><p>2.46 (0.48-12.7)</p><p>0.59 (0.14-2.47)</p><p>NA</p><p>2.6 (0.50-13.4)</p></td><td><p>&nbsp;</p><p>.03</p><p>.002</p><p>.37</p><p>.15</p><p>.27</p><p>.46</p><p>.04</p><p>.24</p></td></tr></tbody></table><p>Abbreviations: CHF, congestive heart failure; CI, confidence interval; MI, myocardial infarction; TIA, transient ischemic attack.</p><p><em>Heart failure:</em></p><p>Haemodynamic studies and exercise based controlled clinical trials in NYHA Class II-IV heart failure patients have shown that amlodipine did not lead to clinical deterioration as measured by exercise tolerance, left ventricular ejection fraction and clinical symptomatology.</p><p>A placebo controlled study (PRAISE) designed to evaluate patients in NYHA Class III-IV heart failure receiving digoxin, diuretics and ACE inhibitors has shown that amlodipine did not lead to an increase in risk of mortality or combined mortality and morbidity with heart failure.</p><p>In a follow-up, long term, placebo controlled study (PRAISE-2) of amlodipine in patients with NYHA III and IV heart failure without clinical symptoms or objective findings suggestive or underlying ischaemic disease, on stable doses of ACE inhibitors, digitalis, and diuretics, amlodipine had no effect on total cardiovascular mortality. In this same population amlodipine was associated with increased reports of pulmonary oedema.</p><p><em>Treatment to prevent heart attack trial (ALLHAT): </em></p><p>A randomized double-blind morbidity-mortality study called the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was performed to compare newer drug therapies: amlodipine 2.5-10 mg/d (calcium channel blocker) or lisinopril 10-40 mg/d (ACE-inhibitor) as first-line therapies to that of the thiazide-diuretic, chlorthalidone 12.5-25 mg/d in mild to moderate hypertension.</p><p>A total of 33,357 hypertensive patients aged 55 or older were randomized and followed for a mean of 4.9 years. The patients had at least one additional CHD risk factor, including: previous myocardial infarction or stroke &gt; 6 months prior to enrollment or documentation of other atherosclerotic CVD (overall 51.5%), type 2 diabetes (36.1%), HDL-C &lt; 35 mg/dL (11.6%), left ventricular hypertrophy diagnosed by electrocardiogram or echocardiography (20.9%), current cigarette smoking (21.9%). &nbsp;</p><p>The primary endpoint was a composite of fatal CHD or non-fatal myocardial infarction. There was no significant difference in the primary endpoint between amlodipine-based therapy and chlorthalidone-based therapy: RR 0.98 (95% CI(0.90-1.07) p=0.65). Among secondary endpoints, the incidence of heart failure (component of a composite combined cardiovascular endpoint) was significantly higher in the amlodipine group as compared to the chlorthalidone group (10.2% vs 7.7%, RR 1.38, (95% CI [1.25-1.52] p&lt;0.001)).</p><p>However, there was no significant difference in all-cause mortality between amlodipine-based therapy and chlorthalidone-based therapy, RR 0.96 (95% CI [0.89-1.02] p=0.20)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The rate and extent of absorption of perindopril and amlodipine from Pratima Duo are not significantly different, respectively, from the rate and extent of absorption of perindopril and amlodipine from individual tablet formulations. &nbsp;</p><p><strong>Perindopril: </strong></p><p><u>Absorption </u></p><p>After oral administration, the absorption of perindopril is rapid and the peak concentration is achieved within 1 hour. The plasma half-life of perindopril is equal to 1 hour.</p><p>Perindopril is a prodrug. Twenty seven percent of the administered perindopril dose reaches the bloodstream as the active metabolite perindoprilat. In addition to active perindoprilat, perindopril yields five metabolites, all inactive. The peak plasma concentration of perindoprilat is achieved within 3 to 4 hours.</p><p>As ingestion of food decreases conversion to perindoprilat, hence bioavailability, perindopril arginine should be administered orally in a single daily dose in the morning before a meal.</p><p>It has been demonstrated a linear relationship between the dose of perindopril and its plasma exposure.</p><p><u>Distribution </u></p><p>The volume of distribution is approximately 0.2 l/kg for unbound perindoprilat. Protein binding of perindoprilat to plasma proteins is 20%, principally to angiotensin converting enzyme, but is concentrationdependent.</p><p><u>Elimination </u></p><p>Perindoprilat is eliminated in the urine and the terminal half-life of the unbound fraction is approximately 17 hours, resulting in steady-state within 4 days.</p><p><u>Elderly, Heart Failure, Renal Failure </u></p><p>Elimination of perindoprilat is decreased in the elderly, and also in patients with heart or renal failure (see section 4.2). Therefore, the usual medical follow-up will include frequent monitoring of creatinine and potassium.</p><p><u>Hepatic impairment </u></p><p>Dialysis clearance of perindoprilat is equal to 70 ml/min.</p><p>Perindopril kinetics are modified in patients with cirrhosis: hepatic clearance of the parent molecule is reduced by half. However, the quantity of perindoprilat formed is not reduced and therefore no dosage adjustment is required (see sections 4.2 and 4.4).</p><p><strong>Amlodipine:</strong></p><p><u>Absorption, distribution, plasma protein binding </u></p><p>After oral administration of therapeutic doses, amlodipine is well absorbed with peak blood levels between 6- 12 hours post dose. Absolute bioavailability has been estimated to be between 64 and 80%. The volume of distribution is approximately 21 l/kg<em>. In vitro</em> studies have shown that approximately 97.5% of circulating amlodipine is bound to plasma proteins.</p><p>The bioavailability of amlodipine is not affected by food intake.</p><p><u>Biotransformation/Elimination </u></p><p>The terminal plasma elimination half-life is about 35-50 hours and is consistent with once daily dosing. Amlodipine is extensively metabolised by the liver to inactive metabolites with 10% of the parent compound and 60% of metabolites excreted in the urine.</p><p><em>Elderly </em></p><p>The time to reach peak plasma concentrations of amlodipine is similar in elderly and younger subjects. Amlodipine clearance tends to be decreased with resulting increases in AUC and elimination half-life in elderly 21 patients. Increases in AUC and elimination half-life in patients with congestive heart failure were as expected for the patient age group studied.</p><p><em>Hepatic impairement<strong>: </strong></em></p><p>Very limited clinical data are available regarding amlodipine administration in patients with hepatic impairment. Patients with hepatic insufficiency have decreased clearance of amlodipine resulting in a longer half-life and an increase in AUC of approximately 40-60%</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Perindopril:</strong></p><p>In the chronic oral toxicity studies (rats and monkeys), the target organ is the kidney, with reversible damage.</p><p>No mutagenicity has been observed in <em>in vitro</em> or <em>in vivo</em> studies.</p><p>Reproduction toxicology studies (rats, mice, rabbits and monkeys) showed no sign of embryotoxicity or teratogenicity. However, angiotensin converting enzyme inhibitors, as a class, have been shown to induce adverse effects on late fetal development, resulting in fetal death and congenital effects in rodents and rabbits: renal lesions and an increase in peri- and postnatal mortality have been observed. Fertility was not impaired either in male or in female rats.</p><p>No carcinogenicity has been observed in long term studies in rats and mice.</p><p><strong>Amlodipine: </strong></p><p><u>Reproductive toxicology </u></p><p>Reproductive studies in rats and mice have shown delayed date of delivery, prolonged duration of labour and decreased pup survival at dosages approximately 50 times greater than the maximum recommended dosage for humans based on mg/kg.</p><p><u>Impairment of fertilitya</u></p><p>There was no effect on the fertility of rats treated with amlodipine (males for 64 days and females 14 days prior to mating) at doses up to 10 mg/kg/day (8 times* the maximum recommended human dose of 10 mg on a mg/m<sup>2</sup> basis). In another rat study in which male rats were treated with amlodipine besilate for 30 days at a dose comparable with the human dose based on mg/kg, decreased plasma follicle-stimulating hormone and testosterone were found as well as decreases in sperm density and in the number of mature spermatids and Sertoli cells.</p><p><u>Carcinogenesis, mutagenesis </u></p><p>Rats and mice treated with amlodipine in the diet for two years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25, and 2.5 mg/kg/day showed no evidence of carcinogenicity. The highest dose (for mice, similar to, and for rats twice* the maximum recommended clinical dose of 10 mg on a mg/m<sup>2</sup> basis) was close to the maximum tolerated dose for mice but not for rats.</p><p>Mutagenicity studies revealed no drug related effects at either the gene or chromosome levels.</p><p>* Based on patient weight of 50 kg</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp; Microcrystalline cellulose</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Colloidal silicone dioxide &nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Magnesium stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p><p>Store in the original package in order to protect from moisture. &nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminum/aluminum blisters.</p><p>Pack size: 30 Tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. BOX 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                08 January 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>